

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 33083-PCT USA	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. OF INVENTOR(S) 37 CFR 097508710	
INTERNATIONAL APPLICATION NO. PCT/GB98/02802		INTERNATIONAL FILING DATE 16 September 1998		PRIORITY DATE CLAIMED 16 September 1997	
TITLE OF INVENTION NEW PLANT GENES					
APPLICANT(S) FOR DO/EO/US COLE, David J.; CUMMINS, Ian; and EDWARDS, Robert					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371 (c)(2)). 7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). 8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 10. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 					
<p>Items 13 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 20. <input checked="" type="checkbox"/> Other items or information: 					
<p>Form PCT/RO/101; Form PCT/IB/304; Form PCT/IB/308; a postcard and a check in the amount of \$1,444.</p> <p>Express Mail No.: EJ594513645US</p> <p>Date of Deposit: Mrch 15, 2000</p>					

U.S. APPLICATION NO. (IF KNOWN) SER. 37 CFR

097508710

INTERNATIONAL APPLICATION NO.

PCT/GB98/02802

ATTORNEY'S DOCKET NUMBER

33083-PCT USA

21. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

- ☒ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$970.00

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). ☐ 20 ☐ 30

\$0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	42 - 20 =	22	x \$18.00	\$396.00
Independent claims	4 - 3 =	1	x \$78.00	\$78.00
Multiple Dependent Claims (check if applicable).			<input type="checkbox"/>	\$0.00

TOTAL OF ABOVE CALCULATIONS =

\$1,444.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐

\$0.00

SUBTOTAL =

\$1,444.00

Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). ☐ 20 ☐ 30 +

\$0.00

TOTAL NATIONAL FEE =

\$1,444.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

\$0.00

TOTAL FEES ENCLOSED =

\$1,444.00

Amount to be
refunded \$
charged \$

- ☒ A check in the amount of **\$1,444.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **02-4377** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Janet M. MacLeod, Ph.D.
Baker Botts LLP
30 Rockefeller Plaza
New York, NY 10112-0228

SIGNATURE

Janet M. MacLeod, Ph.D.

NAME

35,263

REGISTRATION NUMBER

15 March 2000

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : COLE, David J. et al.
Serial No. : To be assigned
Filed : 16 September 1998
For : NEW PLANT GENE

Express Mail Mailing No. EJ594513645US

PRELIMINARY AMENDMENT

Assistant Commissioner of Patent
Box PCT
Washington, D.C., 20231

Sir or Madam:

Prior to examination of the above-identified application, please amend the claims as follows:

IN THE CLAIMS:

Please cancel claims 6, 24, 28, 33, and 45-63 without prejudice.

Claim 3, Line 1: please delete "or 2".

Claim 4, Line 1: please delete "any one of the preceding claims" and substitute therefor --claim 1--.

Claim 7, Line 2: please delete "or 6".

Claim 8, Lines 1-2: please delete "any one of claims 1 to 4" and substitute therefor --claim 1--.

Claim 10, Line 1-2: please delete "any one of claims 1 to 4 or a chimeric gene according to claim 8 or 9".

Claim 12, Line 1: please delete "or 11".

Claim 14, Line 2: please delete "or 9".

Claim 15, Lines 1-2: please delete " , wherein the chimeric gene is a chimeric gene according to claim 9".

- Claim 16, Line 1: please delete "any one of claims 12 to 15" and substitute therefor --claim 12--.
- Claim 17, Line 1: please delete "according to claim 5 or 6".
- Claim 17, Line 3: please delete "any one of claims 12 to 15" and substitute therefor --claim 12--.
- Claim 18, Line 1: please delete "according to claim 7".
- Claim 18, Lines 5-8: please delete "the polypeptide according to claim 5 or 6 and, if a further polynucleotide sequence as defined claim 16 is present, optionally the expression of a further GST subunit encoded by a further polynucleotide" and substitute therefor --a GST polypeptide subunit--.
- Claim 18, Lines 9-10: please delete "according to claim 5 or 6".
- Claim 18, Line 11: please delete "according to claim 7".
- Claim 19, Line 1: please delete "or 18".
- Claim 25, Line 2: please delete "any one of claims 20 to 24" and substitute therefor --claim 20--.
- Claim 26, Line 2: please delete "or 15".
- Claim 27, Lines 2-3: please delete "or 15, or obtainable from a transgenic plant cell, first-generation plant, plant seed or progeny plant according to claim 25".
- Claim 29, Line 2: please delete "any one of claims 1 to 4" and substitute therefor --claim 1--.
- Claim 32, Line 5: please delete "according to claim 7" and substitute therefor --comprising two GST subunits--.
- Claim 32, Line 6: please delete "or 30".
- Claim 32, Line 8-9: please delete "(a) in the construct according to claim 29 or 30" and substitute therefor --encoding a GST subunit--.
- Claim 32, Line 11: please delete "(a) in the construct according to claim 29 or 30".
- Claim 32, Line 14: please delete "according to claim 7".

- Claim 35, Line 3: please delete "according to claim 7".
- Claim 37, Line 2: please delete "or 6".
- Claim 37, Line 2: please delete "according to claim 7" and substitute therefor --comprising said polypeptide--.
- Claim 40, Line 3: please delete "according to claim 35".
- Claim 40, Line 4: please delete "according to claim 37".
- Claim 41, Lines 1-2: please delete "by a method as defined in claim 37 or 38".
- Claim 42, Line 4: please delete "35; or (ii) determining the level of GST mRNA present using a probe according to claim"
- Claim 43, Line 2: please delete "according to any one of claims 25 to 27 is being cultivated".
- Claim 44, Lines 1-2: please delete "any one of claims 34, 35, 39 or 40" and and substitute therefor --claim 34--.

Please add the following claims.


64. A method of determining the GST level in a sample of seed or flour comprising determining the level of GST mRNA present using a probe according to claim 38.
65. A compound identified by the method of claim 39.

REMARKS

The claims have been amended to remove multiple dependencies. Favorable consideration and allowance of all pending claims is respectfully requested.

Respectfully submitted,
BAKER BOTTS LLP

Dated: March 15, 2000


Janet M. MacLeod
Reg. No. 35,263
Attorney for the Applicant
Tel. (212) 705-5000

NEW PLANT GENES**FIELD OF THE INVENTION**

- 5 This invention relates to glutathione transferase (GST) subunits, to nucleic acid sequences encoding glutathione transferase subunits, and to uses of these glutathione transferases and coding sequences, especially in the field of plant biotechnology.

BACKGROUND OF THE INVENTION

10

- Glutathione transferases (GSTs, EC. 2.5.1.18), also referred to as glutathione S-transferases, are multifunctional enzymes capable of catalysing the conjugation of electrophilic substrates with the tripeptide glutathione (GSH, gamma-glutamylcysteinylglycine). The electrophilic substrate may be of natural or synthetic
- 15 origin, examples including endogenous stress-metabolites, drugs, pesticides and pollutants. Conjugation with GSH renders the compounds non-toxic and suitable for export from the cytosol and further metabolism. In addition to their activities in GSH conjugation, GSTs may have additional activities as glutathione peroxidases, catalysing the reduction of organic hydroperoxides to the corresponding alcohol according to the
- 20 reaction:



- All known active GSTs are composed of two polypeptide subunits, with each subunit
- 25 possessing a binding site for GSH and the electrophilic co-substrate. The two subunits may either be identical, giving rise to a homodimer, or dissimilar giving rise to heterodimers. GSTs may therefore be defined according to their source, or class, and their component subunits according to the nomenclature SpGST x-y, where Sp = source or class of GST; x and y describe the subunit types.

30

Each discrete subunit is encoded by a distinct gene, with many eukaryotes containing

GST multigene families encoding multiple isoenzymes.

- The plant in which GSTs have been characterised in the greatest detail is maize (*Zea mays* L.). The major maize GSTs are composed of three discrete subunits, termed I, II and III. These subunits associate together to form three isoenzymes containing the *Zea mays* GST I subunit, namely *ZmGSTI-I*, *ZmGSTI-II* and *ZmGSTI-III* as well as the homodimers *ZmGSTII-II* and *ZmGSTIII-III*. The nucleotide sequences of *ZmGSTI*, *ZmGSTII* and *ZmGSTIII* have been determined. In view of their relatedness in sequence, these maize GSTs have collectively been termed type I plant GSTs.
- Additional maize GSTs with activities toward herbicides have been described as *ZmGSTV-V* and *ZmGSTV-VI*. The sequence of *ZmGSTV* differs markedly from the other maize GSTs described to date, resembling the auxin-inducible GSTs from dicotyledenous plants which have been termed the type III GSTs.
- The maize GST subunit types are associated with differing substrate specificities. The *ZmGSTI* subunit has broad-ranging, but low, activities toward chloro-*s*-triazine, chloroacetanilide and diphenyl ether herbicides. The *ZmGSTII* and *ZmGSTIII* subunits show greater specificity toward chloroacetanilides, while *ZmGSTV* and *ZmGSTVI* are highly active toward diphenyl ethers. The GST isoenzymes differ in their patterns of expression in the organs of maize. Thus, *ZmGSTI-I* and *ZmGSTV-V* are expressed in all plant parts, while *ZmGSTI-II* is root specific. The expression of the GST subunits is also differentially affected by herbicide safeners. These are compounds which enhance the tolerance of cereal crops to herbicides, in part, by increasing the expression of detoxifying enzymes such as GSTs. Thus, the *ZmGSTII* and *ZmGSTV* subunits accumulate in maize seedlings following treatment with the safeners dichlormid or benoxacor while the *ZmGSTI* and *ZmGSTIII* subunits are only modestly enhanced by safeners.

Far less is known regarding GSTs in plant species other than maize. GSTs with activities toward non-herbicide substrates have been identified in some plants, and mRNAs apparently encoding GSTs have been shown to be expressed in plants

including carnation, tobacco and thale cress (*Arabidopsis thaliana*). However, isoenzymes with activities toward herbicides have only been definitively identified in soybean, pea and pine trees. Of these, only in soybean has the nucleotide coding sequences of the herbicide-detoxifying GST been reported.

5

GSTs in plants have also been shown to have secondary activities as glutathione peroxidases, able to reduce organic hydroperoxides, such as fatty acid hydroperoxides to the corresponding monohydroxy alcohols. GSTs with glutathione peroxidase activity have been isolated from peas, soybean, *A. thaliana* and wheat flour. Since fatty acid
10 hydroperoxides are a common result of membrane peroxidation imposed during oxidative stress, glutathione peroxidases provide an important cytoprotective function in preventing the accumulation of fatty acid hydroperoxides and their subsequent degradation to toxic aldehydes. Glutathione peroxidases may therefore have a vital function in protecting plant cells from oxidative stress. The intervention of glutathione
15 peroxidases in lipid peroxidation has also been cited as a determinant of flour quality in wheat.

Of particular relevance to this invention is the lack of knowledge concerning the GSTs of wheat (*Triticum aestivum* L.).

20

Some information is available from experiments on whole plants and plant extracts. Several herbicides including examples of the chloroacetanilides, as well as dimethenamid and fenoxaprop-ethyl undergo GSH conjugation in the course of their detoxification in wheat. Also, in crude plant extracts GST activities toward
25 chloroacetanilide herbicides, dimethenamid and fenoxaprop-ethyl have been demonstrated.

There have been very few reports of the purification of GSTs from wheat. A GST was purified from wheat flour, and described as a homodimer of 27.5 kDa polypeptides with
30 activity toward the non-herbicide substrate 1-chloro-2,4-dinitrobenzene (CDNB) and glutathione peroxidase activity toward fatty acid hydroperoxides. A safener-induced

GST with activity toward CDNB and dimethenamid, termed GSTTaI-I, has been purified and partially sequenced from the wheat progenitor species *Triticum tauschii*, (Reichers et al, (1997), Plant Physiology, 114, pages 1461 to 1470).

- 5 Moreover, very little is known regarding GST genes in wheat. An mRNA originally described as *wir5*, which showed sequence similarity to the type I maize GSTs, was identified as accumulating in wheat leaves during the onset of acquired resistance to powdery mildew (*Erysiphe graminis*). The gene was termed *gstA1* and shown to be similar in genomic organisation to maize *ZmGST1*. The *gstA1* polypeptide was
- 10 expressed in recombinant bacteria and shown to have an apparent molecular mass of 29 kDa. The respective enzyme showed GST activity towards the non-herbicide CDNB, though the activity toward other substrates and activity as a glutathione peroxidase was not reported. An antibody was raised to the recombinant GstA1 and used in Western blotting experiments to show that this GST was specifically induced in wheat leaves by
- 15 pathogen attack. In contrast, a distinct class of GSTs composed of 25 kDa and 26kDa subunits, which were recognised by an antiserum raised to undefined GSTs in maize, accumulated following exposure to cadmium and the herbicides atrazine, alachlor and paraquat. The activities of these xenobiotic-inducible GSTs in wheat and the corresponding nucleotide sequences were not reported. A cDNA corresponding to am
- 20 mRNA encoding a safener-inducible type III GST has been isolated from *Triticum tauschii* and had the same amino acid sequence as GSTTaI-I, (Reicher et al, (1997), Plant Physiology, 114, page 1568).

Thus, although wheat is an important crop plant, there has been little molecular

25 characterisation of wheat GSTs or their genes and, to date, only two purified GSTs and two GST gene sequences, *gstA1* and GSTTaI available.

Significantly, neither purified recombinant GST proteins expressed from gene *gstA1* or GSTTaI were reported to exhibit activity towards herbicides. Hence, none of the

30 previous work on wheat GSTs actually provides any means of achieving herbicide resistance based on the function of wheat GSTs.

SUMMARY OF THE INVENTION

We have purified four GST isoenzymes with activity toward herbicides from wheat shoots treated with the herbicide safener fenchlorazole-ethyl and have identified four distinct subunits. In safener-treated shoots, we have found that the predominant GST subunit is a 25 kDa polypeptide, which has been termed *Triticum aestivum* GST 1 (*TaGST1*). Additionally, two distinct 26 kDa subunits have been identified and termed *TaGST2* and *TaGST3* and a 24 kDa subunit, termed *TaGST4*. These subunits associate together to form the active dimeric isoenzymes *TaGST1-1*, *TaGST1-2*, *TaGST1-3* and *TaGST1-4*.

In our experiments, the expression of all four isoenzymes was affected by the herbicide safener fenchlorazole-ethyl, although each one responds in a somewhat different way.

15 The *TaGST1-1* isoenzyme is the major GST present in the leaves of untreated wheat seedlings, and its expression is increased by approximately 50% following exposure to fenchlorazole-ethyl. *TaGST1-4* is expressed at low levels in untreated shoots and its expression is greatly increased by safener application, while *TaGST1-2* and *TaGST1-3* are only observed following treatment with the safener. All four of these GST

20 isoenzymes have broad-ranging activities toward xenobiotic substrates and all four demonstrate activity towards herbicides and additional activities as glutathione peroxidases able to reduce organic hydroperoxides, with *TaGST1-4* being the most active in this respect. Each isoenzyme also has specific properties. Thus, for example, detoxification of one particular herbicide, fenoxaprop-ethyl, is associated with the more

25 strongly safener-inducible *TaGST1-2*, *TaGST1-3* and *TaGST1-4* heterodimers, rather than with the *TaGST1-1* homodimer.

Furthermore, we have identified, cloned and sequenced cDNAs for the major type III GSTs in wheat, together with cDNAs encoding a range of type I GSTs, all active in

30 herbicide metabolism. This is fundamental to understanding the GST detoxification system in wheat and to exploiting it to generate transgenic herbicide-resistant plants

expressing wheat GSTs. In many previous studies, GST activity could not be linked to specific genes, precluding this approach.

From the sequences of the cDNAs the amino acid sequences of the GST subunits
5 themselves has been deduced.

Accordingly, the invention provides:

a polynucleotide encoding a glutathione transferase (GST) subunit, which
10 polynucleotide comprises a coding sequence capable of hybridising selectively to the coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 to the complement of one of those sequences.

The invention also provides:

15

a polypeptide which is a GST subunit and comprises the amino acid sequence of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18 or a sequence substantially homologous thereto, or a fragment of either said sequence.

20 The invention also provides:

a dimeric protein comprising two GST subunits, wherein at least one subunit is a polypeptide of the invention.

25 The invention also provides:

a chimeric gene comprising a polynucleotide of the invention operably linked to regulatory sequences that allow expression of the coding sequence in a host cell.

30 The invention also provides:

a vector comprising a polynucleotide of the invention or a chimeric gene of the invention.

The invention also provides:

5

a cell transformed or transfected with a vector of the invention.

The invention also provides:

10 a cell having, integrated into its genome, a chimeric gene of the invention.

The invention also provides:

a process for the production of a polypeptide of the invention, which process
15 comprises:

(a) cultivating a cell of the invention under conditions that allow the expression of the polypeptide; and

20 (b) recovering the expressed polypeptide.

The invention also provides:

a process for the production of a dimeric protein of the invention, which process
25 comprises:

(a) cultivating a cell of the invention under conditions that allow:

(i) the expression of the polypeptide of the invention and, if a further polynucleotide sequence as defined herein is present, optionally the expression of a further GST

30 subunit encoded by a further polynucleotide, and

(ii) the association of the GST subunit polypeptide of the invention with another GST

subunit polypeptide to form a dimeric protein of the invention; and

(b) recovering the dimeric protein so formed.

5 The invention also provides:

a method of obtaining a transgenic plant cell comprising:

(a) transforming a plant cell with an expression vector of the invention to give a
10 transgenic plant cell,

and optionally,

(a') transforming the cell with one or more further polynucleotide sequences
15 coding for a GST subunit, operably linked to regulatory elements that allow expression
of the subunit in the cell.

The invention also provides:

20 a method of obtaining a first-generation transgenic plant comprising:

(b) regenerating a transgenic plant cell transformed with a vector of the invention
to give a transgenic plant.

25 The invention also provides:

a method of obtaining a transgenic plant seed comprising:

(c) obtaining a transgenic seed from a transgenic plant obtainable by regenerating
30 a transgenic plant cell transformed with a vector of the invention.

The invention also provides:

a method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant
5 obtainable by regenerating a transgenic plant cell transformed with a vector of the invention, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

The invention also provides:

10

a method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by regenerating a transgenic plant cell transformed with a vector of the invention comprising:

15

(c) obtaining a transgenic seed from a first-generation transgenic plant obtainable by regenerating a transgenic plant cell transformed with a vector of the invention, then obtaining a second-generation transgenic progeny plant from the transgenic seed;

20

and/or

(d) propagating clonally a first-generation transgenic plant obtainable by regenerating a transgenic plant cell transformed with a vector of the invention to give a
25 second-generation progeny plant;

and/or

(e) crossing a first-generation transgenic plant obtainable by regenerating a
30 transgenic plant cell transformed with a vector of the invention with another plant to give a second-generation progeny plant;

and optionally;

- (f) obtaining transgenic progeny plants of one or more further generations from
5 the second-generation progeny plant thus obtained.

The invention also provides:

- a transgenic plant cell, first-generation plant, plant seed or progeny plant obtainable by
10 a method of the invention.

The invention also provides:

- a transgenic plant or plant seed comprising plant cells of the invention.
15

The invention also provides:

- a transgenic plant cell callus comprising plant cells of the invention, or obtainable from
a transgenic plant cell, first-generation plant, plant seed or progeny plant of the
20 invention.

The invention also provides:

- use of a polynucleotide of the invention as a selectable marker for detecting
25 transformation of a plant cell.

The invention also provides:

- a nucleic acid construct comprising:
30

- (a) a polynucleotide of the invention operably linked to regulatory elements that

allow expression of the coding sequence in a plant cell; and

(b) a site into which a further polynucleotide comprising a coding sequence can be inserted.

5

The invention also provides:

a vector comprising such a construct.

10 The invention also provides:

a method of transforming a plant cell or of obtaining a plant cell culture or transgenic plant comprising:

15 (a) providing an untransformed plant cell which is susceptible to a herbicide whose herbicidal activity is reduced by a dimeric protein of the invention;

(b) transforming the plant cell with a vector comprising:

20 (i) a polynucleotide of the invention operably linked to regulatory elements that allow expression of the coding sequence in a plant cell; and

(ii) a site into which a further polynucleotide comprising a coding sequence can be inserted;

25

(c) cultivating the transformed cell under conditions that allow the expression of the polynucleotide (a) in the construct; and/or

(c') regenerating the cell to give a cell culture or plant such that the polynucleotide

30 (a) in the construct is expressed; and

(d) contacting the cell, cell culture or plant with the herbicide whose herbicidal activity is reduced by the dimeric protein of the invention, and to which the untransformed plant cell was susceptible; and

- 5 (e) selecting cells, cell cultures or plants that are less susceptible to the herbicide than are corresponding untransformed cells, cell cultures or plants.

The invention also provides:

- 10 use of a dimeric protein of the invention in a method of identifying compounds capable of metabolism by a GST.

The invention also provides:

- 15 a method of identifying compounds capable of being metabolised by a glutathione transferase comprising:

- (a) contacting a candidate compound suspected of being capable of being metabolised by glutathione transferase with glutathione (GSH) in the presence of a
20 dimeric protein of the invention; and

(b) determining whether or not metabolism of the candidate compound takes place.

- 25 The invention also provides:

compounds identified by such methods.

The invention also provides:

30

a kit for detecting compounds capable of being metabolised by a GST

comprising:

(a) reduced glutathione, hydroxymethylglutathione or
homoglutathione;

5

and

(b) a dimeric protein of the invention.

10 The invention also provides:

an antibody which specifically recognises a polypeptide or dimeric protein of the
invention.

15 The invention also provides:

a nucleic acid probe which selectively hybridises to the sequence of SEQ ID No. 1, 3,
5, 7, 9, 11, 13, 15 or 17.

20 The invention also provides:

a method of identifying compounds that induce GST expression in graminaceous
plants comprising:

25 (a) contacting a graminaceous plant, or a cell or cell culture thereof, with a
candidate compound suspected of being capable of inducing GST expression; and

(b) determining the level of GST expression in the plant, cell or cell culture.

30 The invention also provides:

compounds identified by such methods.

The invention also provides:

- 5 a kit for identifying compounds that induce GST expression in plants by such a method, which kit comprises an antibody of the invention.

The invention also provides:

- 10 a method of determining the GST level in a sample of seed or flour comprising:

(i) determining the level of GST protein present by using an antibody of the invention; or

- 15 (ii) determining the level of GST mRNA present using a probe of the invention.

The invention also provides:

- 20 a method of controlling the growth of weeds at a locus where a transgenic plant of the invention is being cultivated, which method comprises applying to the locus a herbicide whose herbicidal properties are reduced by a dimeric protein of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

25

Figure 1. Anion-exchange chromatography of affinity-purified wheat GSTs.

- Chromatography of A: affinity-purified polar GSTs; and B: affinity-purified hydrophobic GSTs on Hi-Trap Q-Sepharose columns eluted with the increasing NaCl
30 gradient shown. The eluent was monitored for A_{280} as shown with the unbroken line and individual fractions assayed for GST activity.

Figure 2. HPLC analysis of wheat GST subunits.

Reversed-phase HPLC analysis of polypeptide subunits present in A, affinity-purified
5 polar GSTs; B, affinity-purified hydrophobic GSTs; C, the isoenzyme *Ta*GST1-1,
resolved by anion-exchange chromatography of the affinity-purified polar GSTs.

DETAILED DESCRIPTION OF THE INVENTION10 Polynucleotides

The invention provides polynucleotides comprising sequences encoding novel GST
subunits, SEQ ID Nos 1, 3, 5, 7, 9, 11, 13, 15 and 17 and sequences that hybridise
selectively to these coding sequences thereof or their complementary sequences. It also
15 provides polynucleotide fragments of these sequences that encode polypeptides having
GST activity, as defined herein.

A polynucleotide of the invention is capable of hybridising selectively with the coding
sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 or to the sequence
20 complementary to one of those coding sequences. Polynucleotides of the invention
include variants of the coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17
which can function as GSTs, when dimerised with another GST subunit. Typically, a
polynucleotide of the invention is a contiguous sequence of nucleotides which is
capable of selectively hybridising to the coding sequence of SEQ ID. No. 1, 3, 5, 7, 9,
25 11, 13, 15 or 17 or to the complement of that coding sequence.

A polynucleotide of the invention can hybridise to coding sequence of SEQ ID No. 1,
3, 5, 7, 9, 11, 13, 15 or 17 at a level significantly above background. Background
hybridisation may occur, for example, because of other cDNAs present in a cDNA
30 library. The signal level generated by the interaction between a polynucleotide of the
invention and the coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 is

typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ^{32}P . Selective hybridisation is typically achieved using conditions of
5 medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C).

A nucleotide sequence capable of selectively hybridising to the DNA coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 or to the sequence complementary to one
10 of those coding sequences will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95%, 98% or 99%, homologous to the coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 or the complement of one of those sequences over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous nucleotides.

15 Any combination of the above mentioned degrees of homology and minimum sizes may be used to define polynucleotides of the invention, with the more stringent combinations (i.e. higher homology over longer lengths) being preferred. Thus for example a polynucleotide which is at least 90% homologous over 25, preferably over
20 30 nucleotides forms one aspect of the invention, as does a polynucleotide which is at least 95% homologous over 40 nucleotides.

Polynucleotides of the invention may comprise DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A
25 number of different types of modification to polynucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be
30 carried out in order to enhance the *in vivo* activity or lifespan of polynucleotides of the invention.

Polynucleotides of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the
5 polynucleotides may be cloned into vectors. Such primers, probes and other fragments will preferably be at least 10, preferably at least 15 or 20, for example at least 25, 30 or 40 nucleotides in length.

Polynucleotides such as a DNA polynucleotide and primers according to the invention
10 may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. The polynucleotides are typically provided in isolated and/or purified form.

In general, primers will be produced by synthetic means, involving a stepwise
15 manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

Genomic clones corresponding to the cDNAs of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15
20 and 17 containing, for example introns and promoter regions are also aspects of the invention and may also be produced using recombinant means, for example using PCR (polymerase chain reaction) cloning techniques, starting with genomic DNA from a wheat (*Triticum aestivum* L.), cell, e.g. a wheat shoot cell or a cell of a plant of a related *Triticum* species, for example as described by Feldman *et al.*, (Scientific American, (1981), vol. 244(1) pages 98 to 109).

25 Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook *et al.*, 1989, Molecular Cloning: a laboratory manual.

30 Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of

ways.

Other allelic variants of the wheat sequences of SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13, 15 and 17 including those from *Triticum aestivum* L. species itself related to *Triticum aestivum* L. (cf Feldman *et al*, *supra*) may be obtained for example by probing genomic DNA libraries made from a range of wheat cells, using probes as described above.

In addition, other plant homologues of SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13, 15 and 17 may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 or its complement. Such sequences may be obtained by probing cDNA or genomic libraries from other plant species with probes as described above. Degenerate probes can be prepared by means known in the art to take into account the possibility of degenerate variation between the DNA sequences of SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13, 15 and 17 and the sequences being probed for under conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C).

Allelic variants and species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding likely conserved amino acid sequences. Likely conserved sequences can be predicted from aligning the amino acid sequences of the invention (SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 and 18) with that of other similar GST subunit sequences. The primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

Alternatively, such polynucleotides may be obtained by site directed mutagenesis of SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13, 15 or 17 sequences or allelic variants thereof. This may be useful where, for example, silent codon changes are required to sequences to

optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

5

The invention further provides double stranded polynucleotides comprising a polynucleotide of the invention and its complement.

Polynucleotides, probes or primers of the invention may carry a revealing label.

- 10 Suitable labels include radioisotopes such as ^{32}P or ^{35}S , enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides, probes or primers of the invention and may be detected using techniques known *per se*.

- 15 The present invention also provides polynucleotides encoding the polypeptides of the invention described below. Because such polynucleotides will be useful as sequences for recombinant production of polypeptides of the invention, it is not necessary for them to be selectively hybridisable to the coding sequence of sequence SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13, 15 or 17 although this will generally be desirable. Otherwise, such polynucleotides may be labelled, used, and made as described above if desired.
- 20 Polypeptides of the invention are described below.

- Particularly preferred polynucleotides of the invention are those of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 and the polynucleotides that are the coding regions within those sequences i.e. the regions which encode the polypeptides of SEQ ID No. 2, 4, 6, 8, 10,
- 25 12, 14, 16 or 18.

Polypeptides

- A polypeptide of the invention consists essentially of the amino acid sequence set out
- 30 in SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18 or a substantially homologous sequence, or of a fragment of either of these sequences. In general, the naturally occurring amino

acid sequences shown in SEQ ID Nos. 2, 4, 6, 8, 10, 12, 14, 16 or 18 are preferred. However, the polypeptides of the invention include homologues of the natural sequences, and fragments of the natural sequences and of their homologues, which have GST activity.

5

The polypeptides of the invention are glutathione transferase (GST) subunits. The invention also provides dimeric proteins comprising two GST subunits wherein at least one subunit is a polypeptide of the invention.

- 10 Thus, the polypeptides of the invention are normally functionally active as GSTs when dimerised with another GST subunit. Thus, dimeric proteins of the invention are capable of catalysing the conjugation of the tripeptide glutathione (GSH, gamma-glutamylcysteinyl glycine) and/or related derivatives to an electrophilic substrate of natural or synthetic origin. Related derivatives include homoglutathione (gamma-
15 glutamylcysteinyl alanine) and hydroxymethylglutathione (gamma-glutamylcysteinyl serine).

Optionally, they may also have one or more of the other properties of naturally occurring GSTs including glutathione peroxidase activity as defined above.

20

- Preferably, they have GST activity towards one or more herbicide substrates. For example, they may have activity towards one or more of the following herbicides: Fluorodifen, Fenoxaprop-ethyl, Metolachlor, Alpha-Metolachlor, Acetochlor, Alachlor, Pretilachlor, Fluthiamid, Dimethenamid, *S*-Dimethenamid, Flupyrsulfuron-
25 methyl, Triflurosulfuron-methyl, Acifluorfen, Chlorimuron-ethyl, Fomesafen, Atrazine, Simazine, Cyanazine and the sulphatide metabolite of Metribuzin. Particularly preferred herbicides include Fenoxaprop-ethyl, Flupyrsulfuron-methyl, Fluthiamid, Acetochlor, Metolachlor and Alpha-Metolachlor.

- 30 Most preferably, a dimeric protein of the invention is able to catalyse the conjugation of GSH to one or more of the following herbicide substrates: Fenoxaprop-ethyl,

Flupyrsulfuron-methyl, fluthiamid, Acetochlor, Metolachlor and Alpha-Metolachlor.

Optionally, a dimeric protein of the invention may be able to catalyse the conjugation of GSH to one or more non-herbicide substrates, for example CDNB. They may also
5 have activity towards phytotoxic non-herbicide substrates.

Optionally, monomeric polypeptides of the invention may have GST activity as defined above, even when not dimerised.

10 In particular, a polypeptide of the invention may comprise:

- (a) the polypeptide sequence of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18;
- (b) an allelic variant or species homologue thereof; or
- (c) a protein at least 70, 80, 90, 95, 98 or 99% homologous to (a) or (b).

15

An allelic variant will be a variant which will occur naturally in a plant and which will function in a substantially similar manner to the protein of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18, as defined above. Similarly, a species homologue of the protein will be the equivalent protein which occurs naturally in another plant species which can
20 function as GST. Such a homologue may occur in plants other than wheat, particularly monocotyledonous plants such as related *Triticum* species, rice, maize, oats, rye, barley, triticale or sorghum. Within any one species, a homologue may exist as several allelic variants, and these will all be considered homologues of the protein of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18.

25

Allelic variants and species homologues can be obtained by following the procedures described herein for the production of the polypeptides of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 and 18 and performing such procedures on a suitable cell source e.g. a cell of a wheat genotype carrying an allelic variant, or a cell of a plant of a different another
30 species. It will also be possible to use a probe as defined above nucleotide sequence to probe libraries made from plant cells in order to obtain clones encoding the allelic or

species variants. The clones can be manipulated by conventional techniques to generate a polypeptide of the invention which can then be produced by recombinant or synthetic techniques known *per se*.

- 5 A polypeptide of the invention is preferably at least 70% homologous to the protein of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18, more preferably at least 80 or 90% and more preferably still at least 95%, 97% or 99% homologous thereto over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. Methods of measuring protein homology are well known in the art and it
10 will be understood by those of skill in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").

The sequence of the polypeptides of SEQ ID Nos 2, 4, 6, 8, 10, 12, 14, 16 and 18 and
15 of allelic variants and species homologues can thus be modified to provide polypeptides of the invention.

Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions. The modified polypeptide generally retains activity as a GST, as defined
20 herein. Conservative substitutions may be made, for example according to the following Table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.

ALIPHATIC	Non-polar	G A P
		I L V
	Polar-uncharged	C S T M
		N Q
	Polar-charged	D E
		K R
AROMATIC		H F W Y

Polypeptides of the invention also include fragments of the above-mentioned full length polypeptides and variants thereof, including fragments of the sequence set out in SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 and 18. Such fragments typically retain activity as
5 a GST.

Other preferred fragments include those which include an epitope. Suitable fragments will be at least about 5, e.g. 10, 12, 15 or 20 amino acids in size. Polypeptide fragments of the polypeptides of SEQ ID Nos. 2, 4, 6, 8, 10, 12, 14, 16 and 18, and allelic and
10 species variants thereof may contain one or more (e.g. 2, 3, 5, or 10) substitutions, deletions or insertions, including conserved substitutions. Epitopes may be determined either by techniques such as peptide scanning techniques already known in the art. These fragments will be useful for obtaining antibodies to polypeptides and dimeric proteins of the invention.

15 Polypeptides of the invention may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially
20 purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is a polypeptide of the invention.

Polypeptides of the invention may be modified for example by the addition of
25 Histidine residues or a T7 tag to assist their identification or purification or by the addition of a signal sequence to promote their secretion from a cell.

A polypeptide of the invention may be labelled with a revealing label. The revealing label may be any suitable label which allows the polypeptide to be detected. Suitable
30 labels include radioisotopes, e.g. ^{125}I , ^{35}S , enzymes, antibodies, polynucleotides and linkers such as biotin.

Polypeptides and dimeric proteins of the invention may be chemically modified, e.g. post-translationally modified. For example, they may be glycosylated or comprise modified amino acid residues. Such modified polypeptides and proteins fall within the scope of the terms "polypeptide" and "dimeric protein" of the invention.

Dimeric proteins

The invention also provides dimeric proteins having two GST subunits wherein at least one of the two subunits is a polypeptide of the invention. These dimeric proteins may have two identical subunits of the invention, i.e. they may be homodimeric. Alternatively, they may have two dissimilar subunits; i.e. they may be heterodimeric.

In heterodimers, the two subunits may both be polypeptides of the invention. Alternatively, one subunit may be a polypeptide of the invention, whilst the other is a different GST subunit.

Thus, for example, heterodimeric proteins of the invention may have one subunit which is a polypeptide of the invention, and one which is a known GST subunit from maize (e.g. ZmGSTI, ZmGSTII, ZmGSTIII, ZmGSTIV, ZmGSTV or ZmGSTVI: see above), or another species.

Preferably, the dimeric proteins have two subunits that are polypeptides of the invention. Various combinations of polypeptides of the invention are possible. Preferred combinations include:

*Ta*GST1-1 (SEQ ID No. 2/SEQ ID No. 2);
*Ta*GST1-2 (SEQ ID No. 2/SEQ ID No. 16);
*Ta*GST1-3 (SEQ ID No. 2/SEQ ID No. 18);

being

representative of the major combinations found in GSTs in safener-treated

wheat.

The invention also provides dimeric proteins having two subunits as described above which are fusion proteins. In these fusion proteins, the two subunits are joined by a linker polypeptide. Any linker may be used as long as it does not interfere significantly with the correct association of the two subunits or with the GST activity of the dimer. Such fusion proteins will typically be prepared by joining together the polynucleotides encoding the two monomers in the correct reading frame, then expressing the composite polynucleotide coding sequence under the control of regulatory sequences as defined herein. These composite polynucleotide coding sequences are a further aspect of the invention, as are chimeric genes and vectors comprising them, methods of producing them by recombinant means, and cells and plants comprising such vectors or chimeric genes. It will be understood that dimeric proteins of the invention may be such fusion proteins.

15

Vectors and chimeric genes

Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and cultivating the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells are described below in connection with expression vectors. Bacterial cells, especially *E. Coli* are preferred.

Expression vectors

Preferably, a polynucleotide of the invention in a vector is operably linked to regulatory sequences capable of effecting the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. Such expression vectors can be used to

express the polypeptides of the invention.

The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory
5 sequence "operably linked" to a coding sequence is positioned in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequences.

Such vectors may be introduced into a suitable host cell to provide for expression of a
10 polypeptide or polypeptide fragment of the invention, as described below.

The vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication, preferably a promoter for the expression of the said polynucleotide and optionally an enhancer and/or a regulator of the promoter. For
15 expression in plant cells, one preferred enhancer is the Tobacco etch virus (TEV) enhancer. A terminator sequence may also be present, as may a polyadenylation sequence. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene (e.g. *npII* or *nptII*) or methotrexate resistance gene for a plant vector.
20 Vectors may be used *in vitro*, for example for the production of RNA or used to transfect or transform a host cell. The vector may also be adapted to be used *in vivo*, for example for generation of transgenic plants of the invention.

So far as plasmid vectors are concerned, plasmids derived from the Ti plasmid of
25 *Agrobacterium tumefaciens* are especially preferred, as are plasmids derived from the Ri plasmid of *Agrobacterium rhizogenes*.

A further embodiment of the invention provides host cells transformed or transfected with the vectors for the replication and expression of polynucleotides of the invention.
30 The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (bacterial), plant, yeast, insect or mammalian cells, bacterial and plant cells

being preferred.

Polynucleotides according to the invention may also be inserted into the vectors described above in an antisense orientation in order to provide for the production of
5 antisense RNA. Antisense RNA or other antisense polynucleotides may also be produced by synthetic means. Such antisense polynucleotides may be used in a method of controlling the levels of GSTs having the sequence of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18 or their variants or species homologues *in planta*.

10 Promoters and other regulatory elements may be selected to be compatible with the host cell for which the expression vector is designed.

Promoters suitable for use in plant cells may be derived, for example, from plants or from bacteria that associate with plants or from plant viruses. thus, promoters from
15 *Agrobacterium spp.* including the nopaline synthase (nos), octopine synthase (ocs) and mannopine synthase (mas) promoters are preferred. Also preferred are plant promoters such as the ribulose biphosphate small subunit promoter (rubisco ssu), and the phaseolin. promoter. Also preferred are plant viral promoters such as the cauliflower mosaic virus (CAMV) 35S and 19S promoters.

20 Depending on the pattern of expression desired, promoters may be constitutive or inducible. For example, strong constitutive expression in plants can be obtained with the CAMV 35S or rubisco ssu promoters. Also, tissue-specific or stage-specific promoters may be used to target expression of polypeptides of the invention to
25 particular tissues in a transgenic plant or to particular stages in its development. Chemically inducible promoters such as those activated by herbicide safeners may also be used, for example the maize GST 27 promoter (WO97/11189), the maize In2-1 promoter (WO90/11361), the maize In2-2 promoter (De Veylder *et al.*, (1997), Plant Cell Physiology, Vol. 38, pages 568 to 577.

30 Especially where expression in plant cells is desired, other regulatory signals may also

be incorporated in the vector, for example a terminator and/or polyadenylation site. One preferred terminator is the nos terminator although other terminators functional in plant cells may also be used.

- 5 Additionally, sequences encoding secretory signals or transit peptides may be included. On expression, these elements direct secretion from the cell or target the polypeptide of the invention to a particular location within the cell. For example, sequences may be added to target the expressed polypeptide to the nucleus or plastids (e.g. chloroplasts) of a plant cell.

10

Chimeric genes

- The invention also provides chimeric genes suitable for securing the expression of polypeptides of the invention in a host cell, preferably a plant cell. These comprise a
15 polynucleotide of the invention, operably linked to regulatory sequences that allow its expression in a host cell, preferably a plant cell.

- Typically, therefore, a chimeric gene comprises the following elements in 5' to 3' orientation: a promoter functional in a host (preferably plant) cell, as defined above, a
20 polynucleotide of the invention and a terminator functional in said cell, as defined above. Other elements, for example an enhancer, may also be present. These chimeric genes may be incorporated into vectors, as defined above.

Expression in host cells

25

- Expression vectors of the invention may be introduced into host cells using conventional techniques including calcium phosphate precipitation, DEAE-dextran transfection, or electroporation. For plant cells, preferred transformation techniques include electroporation of plant protoplasts, transformation by *Agrobacterium*
30 *tumefaciens* and particle bombardment. Particle bombardment is particularly preferred for transformation of monocot cells.

Expression in the host cell may be transient although, preferably, integration of the polynucleotide or chimeric gene of the invention into the cell's genome is achieved.

5 Suitable cells include cells in which the above-mentioned vectors may be expressed. These include microbial cells such as bacteria such as *E. coli*, plant cells, mammalian cells such as CHO cells, COS7 cells or Hela cells, insect cells or yeast such as *Saccharomyces*. Bacterial and plant cells are preferred.

10 Optionally, cells of the invention may comprise one or more further polynucleotide sequences encoding a GST subunit, operably linked to regulatory sequences, as defined above, that allow expression of the subunit in the cell. Such polynucleotide sequences may be further polynucleotides of the invention or they may encode other GST subunits as defined above with respect to dimeric proteins.

15

Such polynucleotides may be naturally present in the cell, e.g. if it is a plant cell or they may be introduced artificially, e.g. as defined above.

Such cells allow the production of heterodimeric proteins of the invention where the
20 polynucleotides encode different GST subunits, or the production of monomeric polypeptides of the invention and/or homodimeric proteins of the invention in greater quantities. For example, they may allow the expression of active heterodimeric enzymes.

25 Cell culture will take place under standard conditions. Commercially available cultural media for cell culture are widely available and can be used in accordance with manufacturers' instructions.

Processes for production of polypeptides and dimeric proteins

30

The invention provides processes for the production of polypeptides and dimeric

proteins of the invention by recombinant means.

Generally, monomeric GST subunits of the invention spontaneously dimerise to form homodimers and/or heterodimers of the invention. Thus, in general, expression of polypeptides of the invention gives rise to dimers in the first instance. These dimers may be the desired product; alternatively, it may be desirable to separate the monomers. For example, as described below, it may be desired to separate the monomeric subunits of a homodimer in order to combine them with different monomeric subunits, thereby yielding heterodimers.

10

Processes for the production of polypeptides of the invention may comprise:

(a) cultivating a transformed cell as defined above under conditions that allow the expression of the polypeptide;

15

and preferably

(b) recovering the expressed polypeptide.

20 For example, the expressed monomeric peptides may be recovered by denaturation of dimers formed by them, which separates the subunits. Then, the monomers can be recovered and renatured. Typically, they will then redimerise.

Processes for production of dimeric proteins of the invention may comprise:

25

(a) cultivating a transformed cell as defined above under conditions that allow

(i) the expression of the polypeptide of the invention and, if a further GST subunit-encoding sequence as defined above is present, optionally the expression of a further

30 GST subunit encoded by the further sequence

and preferably

- (ii) the association of the GST subunit polypeptide of the invention with another identical GST subunit polypeptide to form a homodimeric protein of the invention; and/or

- (ii) the association of the GST subunit polypeptide of the invention with a non-identical GST subunit to form a heterodimeric protein of the invention.

10

and preferably

- (b) recovering the dimeric proteins so formed, and optionally resolving them.

15 Where only a single type of GST subunit-encoding sequence of the invention is present in the transformed cell, these processes normally give rise to homodimeric proteins of the invention. Where one or more further GST subunit-encoding sequences is present, these processes give rise to heterodimers or to a mixture of some or all of the following: homodimers of each possible type.

20

Alternatively, dimeric proteins of the invention can be produced by expressing the required polypeptide subunits in separate cells. This typically leads to the production of two different types of homodimer. The desired heterodimer can then be prepared by: mixing the homodimers and denaturing the mixed sample, or by denaturing the homodimers separately and then mixing them; then renaturing the mixed sample. This will typically lead to a mixture of dimeric proteins comprising both possible types of homodimers and also heterodimers comprising one subunit of each type. Similarly, mixtures of greater numbers of types of dimer can be produced in this way if different homodimers are produced in three or more different cells, or if cells that give rise to

30 heterodimers are used.

For these processes, any transformed cell as described above may be used. Bacterial cells are preferred, especially cells of *E. coli*, although other cell types may also be used.

- 5 Optionally, the polypeptide or dimeric protein may be isolated and/or purified, by techniques known in the art.

In processes of the invention, any suitable method may be used to denature and/or renature polypeptides of the invention, and suitable methods are well known in the art.

10

Similarly, where a mixture of polypeptide subunits or dimeric proteins results, these may be resolved or separated by any suitable technique known in the art.

Antibodies

15

The invention also provides monoclonal or polyclonal antibodies which specifically recognise polypeptides of the invention or dimeric proteins of the invention.

- 20 Thus, antibodies of the invention bind specifically to the polypeptides and/or dimers of the invention, preferably to the extent that they distinguish between the polypeptides and/or dimers of the invention and other GST subunits and GSTs.

- Monoclonal antibodies may be prepared by conventional hybridoma technology using polypeptides or dimeric proteins of the invention as immunogens. Polyclonal
25 antibodies may also be prepared by conventional means which comprise inoculating a host animal, for example a rat or a rabbit, with a polypeptide of the invention and recovering immune serum. In order that such antibodies may be made, polypeptides may be haptensised to another polypeptide for use as immunogens in animals or humans. For the purposes of this invention, the term "antibody" includes antibody
30 fragments such as Fv, F(ab) and F(ab)₂ fragments, as well as single chain antibodies.

Methods of producing transgenic plant cells, plant parts and tissues, plants and seeds of the invention

Transgenic plant cells, plant parts and tissues, plants and seeds of the invention are
5 transgenic in the sense that they have at least one polynucleotide of the invention introduced into them.

The invention provides a method of obtaining a transgenic plant cell comprising transforming a plant cell with an expression vector of the invention to give a transgenic
10 plant cell; and optionally transforming the cell with one or more further polynucleotide sequences coding for a GST subunit, operably linked to regulatory elements that allow expression of the subunit in the cell. (As discussed above, this allows the production of heterodimeric GST dimers of the invention, or the production of homodimeric ones of the invention in greater quantities.)

15 Any suitable transformation method may be used, for example the transformation techniques described herein. Preferred transformation techniques include electroporation of plant protoplasts, transformation by *Agrobacterium tumefaciens* and particle bombardment. Particle bombardment is particularly preferred for
20 transformation of monocot cells.

The cell may be in any form. for example, it may be an isolated cell, e.g. a protoplast, or it may be part of a plant tissue, e.g. a callus, or a tissue excised from a plant, or it may be part of a whole plant. Transformation may thus give rise to a chimeric tissue or
25 plant in which some cells are transgenic and some are not.

Preferably, integration of a polynucleotide or chimeric gene of the invention into the cell's genome is achieved.

30 The thus obtained cell may be regenerated into a transgenic plant by techniques known in the art. These may involve the use of plant growth substances such as auxins,

giberellins and/or cytokinins to stimulate the growth and/or division of the transgenic cell. Similarly, techniques such as somatic embryogenesis and meristem culture may be used.

- 5 In many such techniques, one step is the formation of a callus, i.e. a plant tissue comprising expanding and/or dividing cells. Such calli are a further aspect of the invention as are other types of plant cell cultures and plant parts. Thus, for example, the invention provides transgenic plant tissues and parts, including embryos, meristems, seeds, shoots, roots, stems, leaves and flower parts. These may be chimeric
10 in the sense that some of their cells are transgenic and some are not.

- Regeneration procedures will typically involve the selection of transformed cells by means of marker genes. Some marker genes have already been mentioned and it should also be noted that the polynucleotides of the invention can themselves act as marker
15 genes if they are under the control of regulatory sequences that allow their expression during the appropriate stage of the regeneration procedure. The polypeptides of the invention are capable of conferring resistance to herbicides or other phytotoxic compounds which are detoxified by GSTs on cells of the invention, as described below. Thus, an appropriate herbicide can be used to select transformants.

- 20 The regeneration step gives rise to a first generation transgenic plant. The invention also provides methods of obtaining transgenic plants of further generations this first generation plant. These are known as progeny transgenic plants. progeny plants of second, third fourth, fifth, sixth and further generations may be obtained from the first
25 generation transgenic plant by any means known in the art.

- Thus, the invention provides a method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant of the invention, and optionally obtaining transgenic plants
30 of one or more further generations from the second-generation progeny plant thus obtained.

Such progeny plants are desirable because the first generation plant may not have all the characteristics required for cultivation. For example, for the production of first generation transgenic plants, a plant of a taxon that is easy to transform and regenerate
5 may be chosen. It may therefore be necessary to introduce further characteristics in one or more subsequent generations of progeny plants before a transgenic plant more suitable for cultivation is produced.

Progeny plants may be produced from their predecessors of earlier generations by any
10 known technique. In particular, progeny plants may be produced by:

obtaining a transgenic seed from a transgenic plant of the invention belonging to a previous generation, then obtaining a transgenic progeny plant of the invention belonging to a new generation by growing up the transgenic seed;

15

and/or

propagating clonally a transgenic plant of the invention belonging to a previous generation to give a transgenic progeny plant of the invention belonging to a new
20 generation;

and/or

crossing a first-generation transgenic plant of the invention belonging to a previous
25 generation with another compatible plant to give a transgenic progeny plant of the invention belonging to a new generation;

and optionally;

30

obtaining transgenic progeny plants of one or more further generations from the

progeny plant thus obtained.

These techniques may be used in any combination. for example, clonal propagation and sexual propagation may be used at different points in a process that gives rise to a
5 transgenic plant suitable for cultivation. In particular, repetitive back-crossing with a plant taxon with agronomically desirable characteristics may be undertaken. Further steps of removing cells from a plant and regenerating new plants therefrom may also be carried out.

10 Also, further desirable characteristics may be introduced by transforming the cells, plant tissues, plants or seeds, at any suitable stage in the above process, to introduce desirable coding sequences other than the polynucleotides of the invention. this may be carried out by the techniques described herein for the introduction of polynucleotides of the invention.

15

For example, further transgenes may be selected from those coding for other herbicide resistance traits; e.g. tolerance to Glyphosate (e.g. using an EPSP synthase gene (e.g. EP-A-0 293,358) or a glyphosate oxidoreductase (WO 92/000377) gene); or tolerance to fosametin; a dihalobenzonitrile; glufosinate (e.g. using a phosphinotricyne acetyl
20 transferase or glutamine synthase gene (cf. EP-A-0 242,236); asulam (e.g. using a dihydropteroate synthase gene (EP-A-0 369,367); or a sulphonylurea (e.g. using an ALS gene); diphenyl ethers such as acifluorfen or oxyfluorfen (e.g. using a protoporphyrinogen oxidase gene); an oxadiazole such as oxadiazon; a cyclic imide such as chlorophthalim; a phenyl pyrazole such as TNP, or a phenopylate or carbamate
25 analogue thereof.

Similarly, genes for beneficial properties other than herbicide tolerance may be introduced. For example, genes for insect resistance may be introduced, notably genes encoding *Bacillus thuringiensis* (*Bt*) toxins.

30

Transgenic plant cells, plant parts and tissues, plants and seeds of the invention

The invention also provides transgenic plant cells, plant parts and tissues, plants and seeds. these are typically obtainable, or obtained, by the methods described above.

- 5 They may be of any botanical taxon, e.g. any species or lower taxonomic grouping. Preferably, they are of a crop plant species.

Transgenic plant cells, plant parts and tissues, plants and seeds of the invention may thus be of a monocotyledonous (monocot) or dicotyledonous (dicot) taxon. Preferred
 10 dicot crop plants include tomato; potato; sugarbeet; cruciferous crops, including oilseed rape; linseed; tobacco; sunflower; fibre crops such as cotton; and leguminous crops such as peas, beans, especially soybean, and alfalfa. Preferred monocots include graminaceous plants such as wheat, maize, rice, oats, barley and rye, sorghum, triticale and sugar cane. Wheat is particularly preferred.

15

Typically, a polypeptide of the invention is expressed in a plant of the invention. depending on the promoter used, this expression may be constitutive or inducible, e.g. by a herbicide safener. similarly, it may be tissue- or stage-specific, i.e. directed towards a particular plant tissue or stage in plant development.

20

Preferably, plant cells, plant parts and tissues, plants and seeds of the invention exhibit herbicide resistance due, at least in part, to expression of a polypeptide of the invention.

- 25 Herbicides to which plants of the invention may be resistant include Fluorodifen, Fenoxaprop-ethyl, Metolachlor, Alpha-Metolachlor, Acetochlor, Alachlor, Pretilachlor, Fluthiamid, Dimethenamid, S-Dimethenamid, Flupyrsulfuron-methyl, Triflurosulfuron-methyl, Acifluorfen, Chlorimuron-ethyl, Fomesafen, Atrazine, Simazine, Cyanazine, and Metribuzin. Particularly preferred herbicides include Fenoxaprop-ethyl,
 30 Flupyrsulfuron-methyl, Fluthiamid, Acetochlor, Metolachlor and Alpha-Metolachlor. Plants of the invention may also exhibit resistance to other herbicides capable of

conjugation to GSH by GSTs or to other non-herbicide phytotoxic substances.

Preferably, a transgenic plant of the invention exhibits resistance to one or more of Fenoxaprop-ethyl, Flupyr-sulfuron-methyl, Fluthiamid, Acetochlor, Metalochlor and
5 Alpha-Metolachlor. Resistance may be exhibited to herbicides which are selective for particular plant taxa and/or herbicides which are generic to all plants.

Uses of the polynucleotides, polypeptides, antibodies, probes and plants of the invention

10

Apart from enabling the generation of herbicide- resistant plants, the invention has a number of other uses.

Selectable markers

15

Polynucleotides of the invention can be used as selectable markers for detecting the transformation of plant cells. When expressed from polynucleotides of the invention, the polypeptides of the invention are capable of conferring herbicide resistance on cells of the invention, as described herein. Thus, an appropriate herbicide can be used to
20 select transformants.

Accordingly, the invention provides a nucleic acid construct comprising:

(a) a polynucleotide of the invention operably linked to regulatory elements that
25 allow expression of a polynucleotide of the invention a plant cell; and

(b) a site into which a further polynucleotide comprising a coding sequence can be inserted.

30 Preferably, site (b) is bounded by regulatory elements that allow expression of a coding sequence inserted at the site in a plant cell.

These constructs may be contained within vectors as described herein.

In these constructs, site (b) is a site into which another nucleic acid sequence can be
5 inserted. in cells transformed with the constructs or vectors containing them,
expression of the polypeptide of the invention can be used as a selectable marker,
indicating that the polynucleotide at site (b) has also been successfully introduced.

In this connection, the invention also provides a method of transforming a plant cell or
10 of obtaining a plant cell culture or transgenic plant comprising:

- (a) providing an untransformed plant cell which is susceptible to a herbicide whose
herbicidal activity is reduced by a dimeric protein of the invention;
- 15 (b) transforming the plant cell with a vector comprising a marker construct of the
invention;
- (c) cultivating the transformed cell under conditions that allow the expression of a
polypeptide of the invention;
- 20 and /or
- (c') regenerating the cell to give a cell culture or plant such that a polypeptide of the
invention is expressed;
- 25 and
- (d) contacting the cell, cell culture or plant with the herbicide whose herbicidal activity
is reduced by a dimeric protein of the invention, and to which herbicide the
30 untransformed plant cell was susceptible;

and

(c) selecting cells, cell cultures or plants that are less susceptible to the herbicide than are corresponding untransformed cells, cell cultures or plants.

5

Identification of novel herbicides

The polypeptides and dimeric proteins of the invention may be used to identify compounds capable of conjugation to GSH. Thus, as conjugation to GSH is the
10 mechanism by which GSTs are believed to effect detoxification of herbicides, the polypeptides of the invention can be used to determine whether or not a candidate herbicidal compound will be detoxified by GSTs, for example the dimeric proteins of the invention. In this case, it may be possible to develop the candidate compound as a herbicide. In particular, it may be possible to develop the candidate compound for
15 selective use as a herbicide on crops of wheat, or of a wheat-related species, or of other plants (cf Feldman *et al supra*), having GSTs with similar activity to the dimeric proteins of the invention. This is because species having such GSTs can be expected to detoxify herbicides identified in the assay.

20 Accordingly, the invention provides a method of identifying compounds capable of conjugation to glutathione comprising:

- (a) contacting a candidate compound suspected of being capable of being metabolised by glutathione transferase with glutathione (GSH) in the presence of a
25 dimeric protein of the invention; and
- (b) determining whether or not metabolism of the candidate compound takes place, or to what extent takes place.

30 Preferably, metabolism of the compound is detected by determining whether, or to what extent, conjugation of the candidate compound to GSH takes place.

Such assay methods may be carried out by any suitable means known in the art. Compounds may be assayed singly, or, preferably, in batches containing several compounds. For example, microtitre plate-based assay techniques may be used. More specifically, the techniques of Example 4 below may be used.

The invention also provides compounds identified by the methods of the invention.

The invention also provides a kit for detecting compounds capable of being metabolised by a GST comprising:

- (a) reduced glutathione, hydroxymethylglutathione or homoglutathione; and
- (b) a dimeric protein of the invention.

15

Such kits may also comprise other components, especially buffer solutions, e.g. aqueous solutions buffered at a suitable pH (e.g. pH7 to pH10, preferably pH7 to pH8).

These kits can be used in the identification of novel herbicides.

20

Identification of compounds that induce GST expression

We have found that expression of the GSTs of the invention is induced by herbicide safeners. As GSTs are implicated in herbicide resistance, it may be desirable to identify other compounds capable of inducing their expression or that of related GSTs in wheat or other plants, preferably graminaceous plants. Such compounds may, for example, be used to induce expression of GSTs involved in herbicide tolerance. This will be beneficial as it will allow crop plants to be selectively protected from herbicides whilst weeds are killed by them.

30

Accordingly, the invention provides a method of identifying compounds that induce

GST expression in graminaceous plants comprising:

- (a) contacting a plant, preferably a graminaceous plant, or a cell or cell culture thereof, with a candidate compound suspected of being capable of inducing GST expression;
- 5 and
- (b) determining the level of GST expression in the plant, cell or cell culture.

Typically, the level of expression is also determined before the compound is added, or
10 in an untreated sample, in order to provide a control. If the level of GST expression in the test sample is higher than that in the control sample then the candidate compound is an inducer of GST expression.

Preferably, the level of GST expression is determined quantitatively although, in
15 certain situations, quantitative detection may suffice, e.g. where the level of expression is zero or undetectable in the absence of an inducer.

Determination of the level of GST expression may be performed by any suitable means. Preferably, it is performed using antibodies or probes of the invention, as
20 described herein.

The invention also provides compounds identified by these methods.

Antibodies that specifically recognise the polypeptides or dimeric proteins of the
25 invention can be used to detect and preferably quantify GST expression by detecting them directly. The antibodies of the invention may thus be used for detecting polypeptides or dimeric proteins of the invention present in plant samples, e.g. by a method which comprises:

- 30 (a) providing an antibody of the invention;
- (b) incubating a plant sample with said antibody under conditions which allow for

the formation of an antibody-antigen complex; and

(c) determining, by any suitable technique known in the art, whether antibody-antigen complex comprising said antibody is formed.

- 5 Antibodies of the invention may be bound to a solid support and/or packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like.

Similarly, polynucleotides or primers of the invention or fragments thereof, labelled or unlabelled, may be used by a person skilled in the art in nucleic acid-based tests for
10 detecting nucleic acid sequences of the invention in a sample taken from a plant, typically a wheat plant.

Such tests generally comprise bringing a sample containing DNA or RNA into contact with a probe comprising a polynucleotide or primer of the invention under hybridising
15 conditions and detecting any duplex formed between the probe and nucleic acid in the sample. Such detection may be achieved using techniques such as PCR or by immobilising the probe on a solid support, removing nucleic acid in the sample which is not hybridised to the probe, and then detecting nucleic acid which has hybridised to the probe.

20 Alternatively, the sample nucleic acid may be immobilised on a solid support, and the amount of probe bound to such a support can be detected.

The probes of the invention may conveniently be packaged in the form of a test kit in a
25 suitable container. In such kits the probe may be bound to a solid support where the assay format for which the kit is designed requires such binding. The kit may also contain suitable reagents for treating the sample to be probed, hybridising the probe to nucleic acid in the sample, control reagents, instructions, and the like.

Measuring the level of GST in batches of seed or flour

Owing to the secondary activity of the GSTs of the invention as glutathione peroxidases, the polypeptides and dimeric proteins of the invention will also have applications in determining the quality of batches of seed and flour, especially of wheat seed, grain and wheat flour. In such batches, glutathione peroxidases are involved in reducing lipid hydroperoxides, which reduces the amount of GSH available. In particular, this occurs during bread making. Thus, it is desirable to be able to monitor the level of GSTs having glutathione peroxidase activity in batches of seed and flour.

10

This can be done by any suitable means. For example, antibodies of the invention can be used to detect polypeptides or dimeric proteins of the invention, as described above. Similarly, probes of the invention can be used to detect GST mRNA, as described above.

15

Alternatively, to determine directly the level of GSH in a batch, the invention provides a method of determining the GSH level in a batch of seed or flour comprising:

- (a) contacting a sample from the batch with a polypeptide or dimeric protein of the invention and a compound whose conjugation to GSH is catalysed by the polypeptide or protein; and
- (b) determining the GSH level from the extent of reaction between the compound and GSH.

25

Controlling the growth of weeds

The invention also provides a method of controlling the growth of weeds at a locus where a transgenic plant of the invention is being cultivated, which method comprises applying a herbicide to the locus. Any amount of herbicide may be used, as long as it is herbicidally effective against the weeds but leaves the herbicide resistant plants of the

invention unaffected, or substantially unaffected. The effect on the weeds may be, for example, to kill them or to inhibit their growth.

Any type of weed that responds to a particular herbicide may be controlled in this way.

- 5 *Alopecurus myosuroides*, *Avena fatua*, *Lolium spp.*, *Bromus spp.*, *Poa annua*, *Galium aparine*, *Aper spica-venti*, *Matricaria inodora*, *Stellaria media*, *Papaver rhoeas*, *Polygonum spp.*, *Setaria sp.*, *Sorghum halapense*, *Panicum miliaceum*, *Echinochloa spp.*, *Digitaria sanguinalis*, *Phalaris minor*, *Abutilon theophrasti*, *Amaranthus retroflexus*, *chenopodium album*, *Datura stramoniuon*, *Solanum nigrum*, *Xanthium*
10 *strumarium*, *saggitaria spp.*, *Monochoria vaginalis*, *Lindernia spp.*, *Eleokaris kurogaai*, *Scirpus juncooides*, *Cyperus spp.*

- The herbicide may, for example, be one whose activity is identified by the methods of the invention (see above). Alternatively, it may be a known herbicide, for example one
15 of the herbicides mentioned herein.

- The herbicide may be applied at any suitable time during the life cycle of the transgenic plant, for example pre-emergence or post-emergence. Timing of application will be tailored to the development of the weeds which it is desired to control. Where
20 inducible or tissue- and/or stage- specific expression of the active dimer of the invention is employed, timing of herbicide application will be tailored to the optimal expression of the invention in the course of the development of the transgenic plant of the invention.

- 25 The following Examples illustrate the invention.

EXAMPLES

Example 1: Isolation and characterisation of the nucleotide sequence 1 encoding *TaGST1*

5

(a) Purification of wheat GST isoenzymes

Wheat GST isoenzymes containing the *TaGST1* subunit were purified by the method of Dixon *et al* (Pestic. Sci. 1997, 50, 72-82). This is summarised below.

10

Wheat seeds (*Triticum aestivum* L. var. Hunter) were imbibed in a 10 mg/l solution of the herbicide safener fenchlorazole-ethyl and then grown in an environmental growth room with further root-applied watering treatments of 5 mg/l fenchlorazole ethyl applied as required. At 10 days after imbibing, the shoot tissue was harvested and
15 extracted prior to precipitation of the protein with ammonium sulphate (80% saturation). The total protein extract was then applied in the presence of 1 M ammonium sulphate to a phenyl-Sepharose column. The bound GSTs were then recovered, firstly by reducing the ammonium sulphate concentration to 0 M to yield the polar GST fraction, which represented 61% of the recovered activity toward 1-
20 chloro-2,4-dinitrobenzene (CDNB). The remaining 39% of the GST activity was then recovered by adding ethylene glycol (50 % v/v) to the running buffer to yield the hydrophobic GST fraction.

The polar and hydrophobic GST fractions were then independently applied to the affinity matrix, *S*-hexyl-glutathione agarose. This matrix bound 90% of the GST
25 activity toward CDNB. Prior to elution of the column with the ligand, *S*-hexyl-glutathione, the matrix was washed with phosphate buffer, followed by phosphate buffer containing 200 mM potassium chloride. The GSTs eluting in this salt wash were termed the "loosely-bound" fraction. Tightly-bound proteins were then eluted with 5 mM *S*-hexyl-glutathione. With both the polar and hydrophobic GSTs an average of
30 34% of the GST activity toward CDNB eluted in the loosely-bound fraction and 66% eluted in the presence of *S*-hexyl-glutathione. The loosely-bound fraction contained the

GSTs which will be considered in Example 2. The major wheat GSTs of interest in this example were found in the affinity-purified pool and to define the numbers of isoenzymes and component subunits present, this pool was analysed in detail.

- 5 When the affinity-bound pools of the polar and hydrophobic GSTs were analysed by anion-exchange chromatography on Q-sepharose, the partial resolution of the eluting activity suggested the presence of multiple isoenzymes (Figure 1). The component polypeptides in the active fractions were then analysed by silver staining after resolution by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
10 PAGE). It was concluded that in fenchlorazole-ethyl-treated wheat the polar GSTs were composed of 25 kDa and 26 kDa polypeptides, while the hydrophobic fraction contained 25kDa, 26 kDa and 24 kDa polypeptides. Further analysis by reversed-phase HPLC confirmed the subunit compositions (Figure 2). Based on the combined analyses by Q-sepharose, HPLC and SDS-PAGE these GST polypeptides were named as
15 described in Table 1, which also contains details of how these subunits associate together to form the active dimers found in plants and the relative abundance of these subunits in extracts from unsafened and fenchlorazole-ethyl treated (safened) plants.

(b) GST activities of the purified *Ta*GST isoenzymes

20

- The purified isoenzymes were assayed for GST activity toward herbicides using the HPLC-based assays described by Edwards R. and Cole D.J. (Pesticide Biochemistry and Physiology Vol. 54, pp96-104 (1996)) and the results are presented in Table 2. Both polar and hydrophobic GSTs from the affinity-bound pools of isoenzymes
25 showed detoxifying activities toward the selective graminicide fenoxaprop-ethyl, the diphenyl-ether herbicide fluorodifen, and the chloracetanilide metolachlor. These isoenzymes had additional activities as glutathione peroxidases able to reduce linoleic acid hydroperoxide, a major reaction product formed during membrane peroxidation in plants (Williamson and Beverly. J. Cereal Sci. 8, 1988, 155-163).

30

(c) Preparation of polyclonal antibodies to the major wheat GST isoenzymes

Purified *TaGST1-1* was used to immunise rabbits to raise polyclonal antibodies to the differing isoenzymes. The reactivity of the antiserum toward crude wheat preparations was demonstrated with a Western blot of polypeptides resolved by SDS-PAGE. The 5 antibodies were then used to identify the corresponding cDNAs in an expression library.

(d) Identification and characterisation of a cDNA encoding *TaGST1*

- 10 An expression library was prepared from poly (A)+ RNA extracted from 7-day wheat shoots grown from seed treated with fenchlorazole-ethyl. The library was constructed in lambda ZAP II (Stratagene) and plaque forming units (pfus) screened with the antiserum raised against *TaGST1-1*. From an initial screen of 170,000 pfus 17 positive plaques were identified, of which 12 were further purified to homogeneity in secondary
- 15 and tertiary screens and the wheat cDNAs excised from the phage to form Bluescript plasmids in *E. coli* SOLR. (Stratagene). Automated DNA sequencing showed that all clones had an identical coding sequence, although differences in the 5' and 3' untranslated regions were apparent, such that of 6 clones sequenced fully on both strands, 4 different untranslated regions were observed. Since these clones shared a
- 20 common open reading frame they were all designated *TaGST1* and then subdivided as A, B, C and D. The nucleotide sequence of *TaGST1* showing the variable untranslated regions of A, B, C and D is shown in SEQ ID No. 1, together with the deduced amino acid sequence of the coding region (SEQ ID No. 2).
- 25 To confirm that *TaGST1* encoded a GST, it was expressed as a fusion protein with beta-galactosidase using the pBluescript plasmid in *E. coli* strain SOLR. *TaGST1* clones were inoculated into LB liquid medium and were grown overnight at 37°C on an orbital shaker in the presence of IPTG. Bacteria were then pelleted by centrifugation, lysed by sonication and assayed for GST activity toward CDNB and analysed by SDS-
- 30 PAGE and Western blotting using the anti-*TaGST1-1* serum. With all six *TaGST1* clones, GST activity toward CDNB could be determined in the crude extracts in the

range 30 - 50 nkat/ mg crude lysate. This was in contrast to control *E. coli* containing the bluescript plasmid without a cDNA insert which showed negligible GST activity (0.2 nkat/mg). When the polypeptides contained in the lysates of the various *TaGST1* clones were analysed by SDS-PAGE, in every case the *TaGST1*-fusion protein was
5 clearly visible as a highly expressed polypeptide relative to the controls. All the fusion proteins reacted with the anti-*TaGST1* serum.

To confirm that the GST activity in the extracts from *TaGST1* clones was due to the fusion protein, the GST-fusion was purified using *S*-hexyl-glutathione agarose affinity
10 chromatography. The pure fusion protein was then assayed for enzyme activity toward herbicide and hydroperoxide substrates and was found to show a similar spectrum of activities to that of the pure *TaGST1*-1 isoenzyme from wheat shoots.

Table 1

Summary of the characteristics of major classes of wheat GST isoenzymes.

- 5 The GST subunits had the following retention times by reversed-phase HPLC.
TaGST1a - 26.4 min, *TaGST1b* - 27.1 min, *TaGST2* - 31.1 min, *TaGST3* - 30.9 min,
TaGST4 - 33.2 min.

ISOENZYME TYPE	SUBUNITS	POLAR (P) OR HYDROPHOBIC (H)	MOLECULAR WEIGHT (KDA)	ANTI- <i>TaGST1</i> ANTIBODY REACTION	% ENHANCEMENT BY SAFENER
<i>TaGST1-1</i>	<i>TaGST1a</i>	P	25	+	30-50
	<i>TaGST1b</i>	P	25	+	30-50
<i>TaGST1-2</i>	<i>TaGST1a</i>	P	25	+	Only
	<i>TaGST1b</i>	P	25	+	observed
	<i>TaGST2</i>	P	26	-	with
					safener
<i>TaGST1-3</i>	<i>TaGST1a</i>	P	25	+	Only
	<i>TaGST1b</i>	P	25	+	observed
	<i>TaGST3</i>	H	26	-	with
					safener
<i>TaGST1-4</i>	<i>TaGST1a</i>	P	25	+	300%
	<i>TaGST1b</i>	P	25	+	300%
	<i>TaGST4</i>	H	24	-	300%

Table 2

Activity of GST isoenzymes purified from fenchlorazole-ethyl-treated wheat shoots.

5

Enzyme activities are expressed as nkcat.mg^{-1}

ISOENZYME	CDNB	FLUORODIFEN	FENOXAPROP -ETHYL	METOLACHLOR
Polar				
TaGST1-1	1,528	0.97	0	0.11
TaGST1-2	1,441	0.38	0.61	0.25
Hydrophobic				
TaGST1-3	1,700	0.38	0.44	0.28
TaGST1-4	1,553	0.57	0.23	0.23

Table 3

CDNB and herbicide activities of recombinant wheat GSTsActivities expressed as $\text{nmol}\cdot\text{mg}^{-1}\cdot\text{min}^{-1} \pm$ standard error

RECOMBINANT ENZYME	CDNB	FLUORODIFEN	FENOXAPROP- ETHYL	METOLACHLOR
TaGST1	1970 ± 30	2.0 ± 0.1	0	0.127 ± 0.014
WIC 1	406.5 ± 0.5	0.136 ± 0.011	0.050 ± 0.010	0.315 ± 0.003
WIC 2	187 ± 1	0.096 ± 0.002	0.085 ± 0.002	0.512 ± 0.04
WIC 3	2,519 ± 88	0.014 ± 0.006	0.093 ± 0.002	0.053 ± 0.004
WIC 4	980 ± 86	0.036 ± 0.004	0.012 ± 0.001	0.037 ± 0.003
WIC 5	174 ± 8	0.030 ± 0.002	0.067 ± 0.003	0.040 ± 0.004
TA 27	237 ± 13	0.034 ± 0.003	0.036 ± 0.004	0.063 ± 0.006
ICR	8139 ± 146	0.037 ± 0.002	0.028 ± 0.001	0.000 ± 0.000
ICC/V/P	30 ± 4	0.000 ± 0.000	0.074 ± 0.008	0.000 ± 0.000

EXAMPLE 2: Cloning of wheat GSTs resembling the type I GSTs from maize.(a) Characterisation of type I GSTs in wheat

- 5 The observation that extracts from safener-treated wheat shoots contained GSTs which, unlike those described in Example 1, were not selectively retained on the affinity matrix suggested that a discrete class of GSTs were present in this loosely bound fraction. Crude extracts of wheat seedlings were analysed by Western blotting following SDS-PAGE using a polyclonal rabbit antiserum raised to the type I
- 10 *ZmGSTII-II* heterodimer. The antiserum reacted strongly with several polypeptides of Mr 23 - 27 kDa. These polypeptides were present in the loosely-bound fraction from the *S*-hexyl-glutathione affinity column, but not in the affinity bound fraction.

(b) Cloning of cDNAs from a wheat expression library

- 15 Having established that safener-treated wheat shoots contained polypeptides which cross-reacted with the antiserum raised to the maize GSTs, the primary cDNA expression library prepared from fenchlorazole-ethyl treated wheat shoots was screened with the antibody for positive clones. Following a screen of 170,000 pfu, ten positive plaques were identified, with obvious differences in the intensity of
- 20 recognition, with four plaques showing a strong colour reaction and six plaques of lower intensity. These cDNA clones were termed *WIC* clones. All four of the stronger-reacting plaques (*WIC* 1, 2, 4 and 5) and four of the weaker positives (*WIC* 3, 7, 8 and 10) were purified to homogeneity, the respective plasmids excised and DNA preparations sequenced. The clones were then grouped by their degree of similarity in
- 25 sequence.

In the sequence listing, *WIC* 1 is SEQ ID No. 3 and its deduced amino acid sequence is SEQ ID No. 4. *WIC* 2 is SEQ ID No. 5 and its deduced amino acid sequence is SEQ ID No. 6. The coding sequences of *WIC* 3, *WIC* 7 and *WIC* 8 were identical in

30 sequence. The DNA sequence of *WIC* 3/7/8 is given in SEQ ID No. 7 and the deduced amino acid sequence in SEQ ID No. 8. All three sequences contained a stop codon in

the 5' untranslated region of the GST gene, although some expression occurred. The DNA sequence of WIC 5 is shown in SEQ ID No. 9, and the deduced amino acid sequence in SEQ ID No. 10. WIC 4 and WIC 10 had identical coding sequences, but differed in their untranslated regions. In particular, WIC 10 had a stop codon in the 5' untranslated region, though this did not prevent all expression of the fusion protein. The WIC 4 DNA sequence is given in SEQ ID No. 11 and the deduced WIC 4/10 amino acid sequence in SEQ ID No. 12 (the WIC 10 DNA sequence is not shown).

(c) Cloning of wheat GSTs by differential screening of a cDNA library

10 A further cDNA clone, termed *TA 27* was obtained. A cDNA library prepared from wheat seedlings treated with the herbicide safener cloquintocet-mexyl, was screened for clones which represented mRNAs which were differentially expressed in wheat in response to safener application. The identity of the clone as a GST was suggested from its nucleotide (SEQ ID No. 13) and deduced amino acid (SEQ ID No. 14) sequence. As
15 the coding sequence of *TA 27* was not in frame with beta-galactosidase in the pBluescript vector, the coding sequence was sub-cloned into the expression vector pET 11a (Novagen), with translation starting at the first ATG codon in the clone, which gave a reasonable alignment of the open reading frame with that of other GSTs involved in herbicide metabolism, notably the *ZmGSTIV* sequence.

20

(d) Activity of recombinant GSTs of the invention

To confirm that the *WIC* clones and *TA 27* encoded functional GSTs the corresponding enzymes were expressed as recombinant enzymes in *E. coli*. The full coding sequence of *TA 27* was expressed in the pET vector, while the *WIC* clones were expressed as
25 fusions with part of the beta-galactosidase enzyme using the pBluescript vector. The levels of recombinant protein expressed varied between the differing clones. Appreciable amounts of recombinant protein were observed in the *TA 27* pET clones and in clones *WIC 1*, *WIC 2*, *WIC 4* and *WIC 5*. Western blotting of these total bacterial extracts with the antiserum raised to *ZmGSTI-II* showed that the fusion
30 proteins were selectively recognised by the antiserum. In contrast, use of the antiserum demonstrated much lower levels of expression of immunoreactive fusion proteins in

clones WIC 3, WIC 7, WIC 8 and WIC 10.

To assay the recombinant fusion proteins for GST activity, the *E. coli* were grown in the presence of IPTG and then pelleted by centrifugation. The bacteria were then lysed
5 by sonication and the protein precipitated using 80% ammonium sulphate. After resuspension and desalting, GSTs were purified by affinity chromatography. The WIC 3 fusion protein was purified using sulphobromophthalein-S-glutathione affinity chromatography (Mozer *et al.* Biochem. 22, 1983, 1068-1072) while the other WIC fusion proteins were purified using glutathione-agarose (Mannervik and Guthenberg.
10 Methods Enzymol. 77, 1981, 231-235). The purified enzymes were then assayed for GST activities toward herbicides (Table 3) and GST activities toward non-herbicide substrates and glutathione peroxidase activities toward organic hydroperoxides (Table 4).

Table 4

Other GST activities and glutathione peroxidase activities.

- 5 Activities expressed as $\text{nkat.mg}^{-1} \pm \text{standard error}$. Peroxidase activities expressed as absorbance change at $340 \text{ nm.mg}^{-1} \pm \text{standard error}$ ($n=3$). N.D = not detected, - not performed.

	CUMENE HYDROPEROXIDE	BENZYL ISOTHIOCYANATE	CROTONALDEHYDE	ETHACRYNIC ACID
WIC 1	18.6 ± 0.5	18.0 ± 3.75	7.1 ± 0.7	N.D.
WIC 2	28.2 ± 1.7	33.3 ± 4.5	5.5 ± 1.3	N.D.
WIC 3	1.4 ± 0.3	9.0 ± 0.5	6.3 ± 0.9	N.D.
WIC 4	6.2 ± 0.3	4.2 ± 0.4	5.5 ± 0.6	1.4 ± 0.3
WIC 5	1.3 ± 0.2	9.4 ± 2.0	4.5 ± 0.5	N.D.
TaGST1	0.7 ± 0.1	11.8 ± 0	3.7 ± 0.3	N.D.
TA 27	3.6 ± 0.4	-	-	-
ICR	N.D	-	-	-
ICC/V/P	0.84 ± 0.04	-	-	-

Example 3: Cloning of safener-inducible type III GSTs from wheat.

A polyclonal antiserum was raised in a rabbit to a mixture of TaGST1-2 and TaGST1-3. When tested against crude extracts from safener-treated wheat shoots the antiserum recognised both the 25 kDa TaGST1 subunit and the 26 kDa safener-inducible TaGST2 and TaGST3 subunits. The antiserum was then used in conjunction with the antiserum raised to TaGST1-1 to immuno screen the cDNA library prepared from fenchlorazole ethyl treated wheat shoots as described in example 1. Duplicate lifts were taken from the plated out library and the first blot screened with the antiserum raised against TaGST1-2 and TaGST1-3. The second blot was screened with the antiserum raised to TaGST1-1. Five plaques were identified from the first blot which were absent from the second blot corresponding to cDNAs encoding TaGST2 or TaGST3 like polypeptides and these clones were purified and the respective plasmids sequenced. One of the clones, termed ICJ had an identical nucleotide sequence to *GST Tsl*, a safener-inducible GST identified in *Triticum tauschii* (Riechers et al., 1997 Plant Physiol. 114, 1568). Another clone, ICR, though showing some similarity to ICJ had a novel coding DNA coding sequence (SEQ ID No. 15) and predicted amino acid sequence (SEQ ID No. 16). The other three clones ICC, ICP and ICV had identical DNA sequences (SEQ ID No. 17) and predicted amino acid sequence (SEQ ID No. 18). GST ICJ was sub-cloned into the pET 11a vector after using PCR to introduce a Nde I restriction site into the translation start site, using the primer 5' AGG TAG TTA CAT ATG GCC GGA GGA 3' (SEQ ID No. 19) in the amplification. Following sub-cloning, the sequence of GST ICJ was re-checked to ensure no PCR induced errors had been introduced. The recombinant GST ICJ was then expressed in *E. coli* and purified by *S*-hexylglutathione affinity chromatography. The purified GST ICJ was assayed for activities as a GST (Table 3) and as a glutathione peroxidase (Table 4). The clone GST ICV was expressed in a variety of vectors, but in all cases the recombinant proteins proved impossible to purify using a variety of affinity columns (*S*-hexylglutathione-agarose, *S*-bromosulphophthalein glutathione agarose). GST ICV was finally expressed as the respective beta-galactosidase fusion protein using the Bluescript plasmid and assayed for GST activity (Table 3) and glutathione peroxidase activity

(Table 4) in crude bacterial lysates. The specific activity of GST ICV toward these substrates was then calculated by i) subtracting the low levels of GST and GPOX activity present due the endogenous activities in the *E.coli* and ii) determining the proportion of protein in the lysate present as recombinant GST ICV from SDS-PAGE analysis, by densitometry analysis of polypeptides stained with Coomassie blue .

EXAMPLE 4: A microtitre plate - based screen to identify herbicidal molecules which are metabolised by GSTs of the invention and may selectively control weeds in a crop of wheat or other species such as maize, soybean or rice

10

(a) Degradation of candidate herbicides by wheat GSTs and relationship to crop and weed selectivity

Herbicidal molecules which are degraded by recombinant wheat GSTs may be predicted to be tolerated by plants of wheat or other crop species. These herbicides may be less rapidly degraded in weeds such as black-grass (*Alopecurus myosuroides*) which are desirable to control in a crop of wheat or other species. Herbicides found in a laboratory based screen to be metabolised by these GSTs are therefore likely to possess useful abilities to selectively control troublesome weeds in a crop of wheat, or other species such as maize, soybean, rice, cotton, barley, oat, rye, sorghum, triticale, potato, sugarcane or sugarbeet.

20

(b) A 96 well plate - based assay procedure for identifying novel herbicides degraded by recombinant wheat GSTs

25

Novel herbicides arising from a chemical synthesis programme oriented to optimisation for selective herbicidal activity and potency may be screened for ability to be degraded by a panel of recombinant GSTs using a 96 well microplate assay format and subsequent reaction analysis by automated High Pressure Liquid Chromatography (HPLC). This allows for example, the screening of a set of eleven novel herbicides and one positive control compound such as CDNB, against a panel of seven recombinant

30

GSTs. An eighth file of wells contains test compounds but lacks GSTs; these wells serve to identify non-enzymic reaction of the test compounds with reduced glutathione. Alternatively, the array can be configured to screen more test compounds against a more limited number of GSTs. For example, fifteen compounds can be screened against five GSTs or forty seven compounds may be screened with a single mixture of GSTs. In all cases, provision is made for a positive control and to test for non-enzymic reaction with reduced glutathione.

Enzyme assays are carried out in a total reaction volume of 100 microlitres. Each reaction mixture contains 100 micromolar Tris.HCl buffer, pH 7.8, 500 micromolar reduced glutathione and where appropriate, 500 micromolar test compound or a reference substrate such as CDNB; and 14 micrograms of GST protein. The microplate is incubated at 30°C on a variable speed agitator for 30 minutes and reactions are then stopped by the addition of 15 microlitres of 23% perchloric acid solution. The microplate is then centrifuged at 2000 g for 15 minutes.

(c) Reaction analysis by automated High Pressure Liquid Chromatography.

The separation and analysis of glutathione conjugates of test herbicides may be carried out using High Pressure Liquid Chromatography (HPLC), for example a Gilson HPLC in tandem with corresponding software, for example Gilson Version 7.12 and fitted with an appropriate column, for example a 5 cm Spherisorb ODS2 column. Typically, separation may be carried out using a two phase solvent system as follows: Phase A: water containing 0.1% trifluoroacetic acid and 5.5% acetonitrile; Phase B: 100% acetonitrile; flow rate 1.5 ml per minute; injection volume 20 microlitres.

The elution gradient may be typically as follows: 10% phase B for one minute, followed by a linear gradient to reach 60% phase B after 8.5 minutes. The gradient is further increased to reach 100% phase B at 9 minutes; phase B is continued at 100% until 11.5 minutes and is then reduced in a linear gradient to 10% at 13.5 minutes. A further 1.5 minutes at 10% phase B is required to re-equilibrate the column.

Absorbance signals are detected at 264 nanometres using a suitable UV detector, and detect the glutathione conjugate of CDNB, having a retention time of 2.4 minutes, resolving this from unreacted CDNB having a retention time of 4.75 minutes. Such conditions also allow for the resolution and detection of the glutathione conjugates
5 arising from the metabolism of other reference herbicides such as metolachlor, fenoxaprop, fenoxaprop-ethyl and fluorodifen and also of a variety of novel herbicidal compounds identified in the assay.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

CLAIMS

1. A polynucleotide encoding a glutathione transferase (GST) subunit, which polynucleotide comprises a coding sequence capable of hybridising selectively to the coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 or to the complement of one of those sequences.
2. A polynucleotide of claim 1 which is a DNA sequence.
3. A polynucleotide according to claim 1 or 2 wherein the coding sequence encodes the amino acid sequence of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18.
4. A polynucleotide according to any one of the preceding claims which comprises the coding sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17 or a fragment thereof.
5. A polypeptide which is a GST subunit and comprises the amino acid sequence of SEQ ID No. 2, 4, 6, 8, 10, 12, 14, 16 or 18 or a sequence substantially homologous thereto, or a fragment of either said sequence.
6. A polypeptide according to claim 5 encoded by the coding sequence of a polynucleotide according to any one of claims 1 to 4.
7. A dimeric protein comprising two GST subunits, wherein at least one subunit is a polypeptide according to claim 5 or 6.
8. A chimeric gene comprising a polynucleotide according to any one of claims 1 to 4 operably linked to regulatory sequences that allow expression of the coding sequence in a host cell.

9. A chimeric gene according to claim 7 wherein the regulatory sequences allow expression of the coding sequence in a plant cell.
10. A vector comprising a polynucleotide according to any one of claims 1 to 4 or a chimeric gene according to claim 8 or 9.
11. A vector according to claim 10 which is an expression vector.
12. A cell transformed or transfected with a vector according to claim 10 or 11.
13. A cell according to claim 12 which is a prokaryotic cell or a plant cell.
14. A cell having, integrated into its genome, a chimeric gene according to claim 8 or 9.
15. A cell according to claim 14 which is a plant cell, wherein the chimeric gene is a chimeric gene according to claim 9.
16. A cell according to any one of claims 12 to 15 further comprising one or more further polynucleotide sequences coding for a GST subunit, operably linked to regulatory elements that allow expression of the subunit in the cell.
17. A process for the production of a polypeptide according to claim 5 or 6, which process comprises:
 - (a) cultivating a cell according to any one of claims 12 to 15 under conditions that allow the expression of the polypeptide; and
 - (b) recovering the expressed polypeptide.

18. A process for the production of a dimeric protein according to claim 7, which process comprises:
- (a) cultivating a cell according to any one of claims 12 to 16 under conditions that allow:
 - (i) the expression of the polypeptide according to claim 5 or 6 and, if a further polynucleotide sequence as defined in claim 16 is present, optionally the expression of a further GST subunit encoded by a further polynucleotide, and
 - (ii) the association of the GST subunit polypeptide according to claim 5 or 6 with another GST subunit polypeptide to form a dimeric protein according to claim 7; and
 - (b) recovering the dimeric protein so formed.
19. A process according to claim 17 or 18 wherein the cell is a prokaryotic cell or a plant cell.
20. A method of obtaining a transgenic plant cell comprising:
- (a) transforming a plant cell with an expression vector according to claim 11 to give a transgenic plant cell,
- and optionally,
- (a') transforming the cell with one or more further polynucleotide sequences coding for a GST subunit, operably linked to regulatory elements that allow expression of the subunit in the cell.

21. A method of obtaining a first-generation transgenic plant comprising:
- (b) regenerating a transgenic plant cell transformed with a vector according to claim 11 to give a transgenic plant.
22. A method of obtaining a transgenic plant seed comprising:
- (c) obtaining a transgenic seed from a transgenic plant obtainable by step (b) of claim 21.
23. A method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by a method according to claim 21, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.
24. A method according to claim 23 comprising:
- (c) obtaining a transgenic seed from a first-generation transgenic plant obtainable by the method according to claim 21, then obtaining a second-generation transgenic progeny plant from the transgenic seed;
- and/or
- (d) propagating clonally a first-generation transgenic plant obtainable by the method according to claim 21 to give a second-generation progeny plant;
- and/or
- (e) crossing a first-generation transgenic plant obtainable by a method according to claim 21 with another plant to give a second-generation

progeny plant;

and optionally;

(f) obtaining transgenic progeny plants of one or more further generations from the second-generation progeny plant thus obtained.

25. A transgenic plant cell, first-generation plant, plant seed or progeny plant obtainable by a method according to any one of claims 20 to 24.
26. A transgenic plant or plant seed comprising plant cells according to claim 13 or 15.
27. A transgenic plant cell callus comprising plant cells according to claim 13 or 15, or obtainable from a transgenic plant cell, first-generation plant, plant seed or progeny plant according to claim 25.
28. Use of a polynucleotide according to any one of claims 1 to 4 as a selectable marker for detecting transformation of a plant cell.
29. A nucleic acid construct comprising:
 - (a) a polynucleotide according to any one of claims 1 to 4 operably linked to regulatory elements that allow expression of the coding sequence in a plant cell; and
 - (b) a site into which a further polynucleotide comprising a coding sequence can be inserted.
30. A nucleic acid construct according to claim 29 wherein site (b) is bounded by regulatory elements that allow expression of a coding sequence inserted

at the site in a plant cell.

31. A vector comprising a construct according to claim 29.
32. A method of transforming a plant cell or of obtaining a plant cell culture or transgenic plant comprising:
- (a) providing an untransformed plant cell which is susceptible to a herbicide whose herbicidal activity is reduced by a dimeric protein according to claim 7;
 - (b) transforming the plant cell with a vector according to claim 29 or 30;
 - (c) cultivating the transformed cell under conditions that allow the expression of the polynucleotide (a) in the construct according to claim 29 or 30; and/or
 - (c') regenerating the cell to give a cell culture or plant such that the polynucleotide (a) in the construct according to claim 29 or 30 is expressed; and
 - (d) contacting the cell, cell culture or plant with the herbicide whose herbicidal activity is reduced by the dimeric protein according to claim 7, and to which the untransformed plant cell was susceptible; and
 - (e) selecting cells, cell cultures or plants that are less susceptible to the herbicide than are corresponding untransformed cells, cell cultures or plants.
33. Use of a dimeric protein according to claim 7 in a method of identifying compounds capable of metabolism by a GST.

34. A method of identifying compounds capable of being metabolised by a glutathione transferase comprising:
- (a) contacting a candidate compound suspected of being capable of being metabolised by glutathione transferase with glutathione (GSH) in the presence of a dimeric protein according to claim 7; and
 - (b) determining whether or not metabolism of the candidate compound takes place.
35. A method according to claim 34 wherein metabolism of the compound is detected by determining whether or not it is conjugated to glutathione by the dimeric protein according to claim 7.
36. A kit for detecting compounds capable of being metabolised by a GST comprising:
- (a) reduced glutathione, hydroxymethylglutathione or homoglutathione;
- and
- (b) a dimeric protein according to claim 7.
37. An antibody which specifically recognises a polypeptide according to claim 5 or 6 or a dimeric protein according to claim 7.
38. A nucleic acid probe which selectively hybridises to the sequence of SEQ ID No. 1, 3, 5, 7, 9, 11, 13, 15 or 17.
39. A method of identifying compounds that induce GST expression in

graminaceous plants comprising:

(a) contacting a graminaceous plant, or a cell or cell culture thereof, with a candidate compound suspected of being capable of inducing GST expression; and

(b) determining the level of GST expression in the plant, cell or cell culture.

40. A method according to claim 39 wherein, in step (b), the level of expression is determined by: (i) determining the level of GST protein present by using an antibody according to claim 35; or (ii) determining the level of GST mRNA present using a probe according to claim 37.
41. A kit for identifying compounds that induce GST expression in plants by a method as defined in claim 37 or 38, which kit comprises an antibody as defined in claim 36.
42. A method of determining the GST level in a sample of seed or flour comprising:
- (i) determining the level of GST protein present by using an antibody according to claim 35; or
- (ii) determining the level of GST mRNA present using a probe according to claim 37.
43. A method of controlling the growth of weeds at a locus where a transgenic plant according to any one of claims 25 to 27 is being cultivated, which method comprises applying to the locus a herbicide whose herbicidal properties are reduced by a dimeric protein according to claim 7.

44. A compound identified by a method according to any one of claims 34, 35, 39 or 40.
45. A polynucleotide according to claim 1 substantially as hereinbefore described with reference to any one of the preceding Examples.
46. A polypeptide according to claim 5 substantially as hereinbefore described with reference to any one of the preceding Examples.
47. A dimeric protein according to claim 7 substantially as hereinbefore described with reference to any one of the preceding Examples.
48. A chimeric gene according to claim 8 substantially as hereinbefore described with reference to any one of the preceding Examples.
49. A vector according to claim 10 substantially as hereinbefore described with reference to any one of the preceding Examples.
50. A cell according to claim 12 substantially as hereinbefore described with reference to any one of the preceding Examples.
51. A process according to claim 17 or 18 substantially as hereinbefore described with reference to any one of the preceding Examples.
52. A method according to claims 20, 21, 22 or 23 substantially as hereinbefore described with reference to any one of the preceding Examples.
53. A transgenic plant cell, first-generation plant, plant seed or progeny plant, plant or plant seed, or plant cell callus according to any one of claims 25 to 27 substantially as hereinbefore described with reference to any one of the preceding Examples.

54. Use according to claim 28 substantially as hereinbefore described with reference to any one of the preceding Examples.
55. A nucleic acid construct according to claim 29 substantially as hereinbefore described with reference to any one of the preceding Examples.
56. A vector according to claim 31 substantially as hereinbefore described with reference to any one of the preceding Examples.
57. A method according to claim 32 substantially as hereinbefore described with reference to any one of the preceding Examples.
58. Use according to claim 33 substantially as hereinbefore described with reference to any one of the preceding Examples.
59. A method according to claim 34 substantially as hereinbefore described with reference to any one of the preceding Examples.
60. An antibody according to claim 37 substantially as hereinbefore described with reference to any one of the preceding Examples.
61. A nucleic acid probe according to claim 38 substantially as hereinbefore described with reference to any one of the preceding Examples.
62. A method according to claims 39, 42 or 43 substantially as hereinbefore described with reference to any one of the preceding Examples.
63. A compound according to claim 44 substantially as hereinbefore described with reference to any one of the preceding Examples.

Fig.1A.








Fig.1B.







COMBINED DECLARATION AND POWER OF ATTORNEY

(Original, Design, National Stage of PCT, Divisional, Continuation or C-I-P Application)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NEW PLANT GENES

This declaration is of the following type:

- ☐ original
- ☐ design
- ☒ national stage of PCT.
- ☐ divisional
- ☐ continuation
- ☐ continuation-in-part (C-I-P)

the specification of which: *(complete (a), (b), or (c))*

- (a) ☐ is attached hereto.
- (b) ☒ was filed on March 15, 2000 as Application Serial No. 09/508,710 and was amended on *(if applicable)*.
- (c) ☒ was described and claimed in PCT International Application No. PCT/GB98/02802 filed on September 16, 1998 and was amended on *(if applicable)*.

Acknowledgement of Review of Papers and Duty of Candor

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of the subject matter claimed in this application in accordance with Title 37, Code of Federal Regulations § 1.56.

☐ In compliance with this duty there is attached an information disclosure statement. 37 CFR 1.98.

Priority Claim

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed

(complete (d) or (e))

- (d) ☐ no such applications have been filed.
- (e) ☒ such applications have been filed as follows:



PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY	APPLICATION NO.	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
United Kingdom	971972.1	September 16, 1997	
			PRIORITY CLAIMED UNDER 35 USC 119 <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

Claim for Benefit of Prior U.S. Provisional Application(s)

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number	Filing Date

Claim for Benefit of Earlier U.S./PCT Application(s) under 35 U.S.C. 120

(complete this part only if this is a divisional, continuation or C-I-P application)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

Power of Attorney

As a named inventor, I hereby appoint Dana M. Raymond, Reg. No. 18,540; Frederick C. Carver, Reg. No. 17,021; Francis J. Hone, Reg. No. 18,662; Joseph D. Garon, Reg. No. 20,420; Arthur S. Tenser, Reg. No. 18,839; Ronald B. Hildreth, Reg. No. 19,498; Thomas R. Nesbitt, Jr., Reg. No. 22,075; Robert Neuner, Reg. No. 24,316; Richard G. Berkley, Reg. No. 25,465; Richard S. Clark, Reg. No. 26,154; Bradley B. Geist, Reg. No. 27,551; James J. Maune, Reg. No. 26,946; John D. Murmane, Reg. No. 29,836; Henry Tang, Reg. No. 29,705; Robert C. Scheinfeld, Reg. No. 31,300; John A. Fogarty, Jr., Reg. No. 22,348; Louis S. Sorell, Reg. No. 32,439; Rochelle K. Seide Reg. No. 32,300; Gary M. Butter, Reg. No. 33,841; Marta E. Delsignore, Reg. No. 32,689; and Lisa B. Kole, Reg. No. 35,225 of the firm of BAKER BOTTS L.L.P., with offices at 30 Rockefeller Plaza, New York, New York 10112, as attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

SEND CORRESPONDENCE TO: BAKER BOTTS L.L.P. 30 ROCKEFELLER PLAZA, NEW YORK, N.Y. 10112 CUSTOMER NUMBER: <u>21003</u>	DIRECT TELEPHONE CALLS TO: BAKER BOTTS L.L.P. (212) 705-5000
--	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge

that willful false statements and the like, so made, shall be punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	LAST NAME <u>COLE</u>	FIRST NAME <u>DAVID</u>	MIDDLE NAME <u>J.</u>
RESIDENCE & CITIZENSHIP	CITY <u>Essex</u> <u>GBX</u>	STATE or FOREIGN COUNTRY <u>United Kingdom</u>	COUNTRY OF CITIZENSHIP <u>United Kingdom</u>
POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Fyfield Road, Ongar</u>	CITY <u>Essex</u>	STATE or COUNTRY <u>United Kingdom</u> ZIP CODE <u>CMS 0HW</u>
DATE <u>30 May 2005</u>	SIGNATURE OF INVENTOR <u>David Cole</u>		
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	LAST NAME <u>CUMMINS</u>	FIRST NAME <u>IAN</u>	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY <u>Durham</u> <u>GBX</u>	STATE or FOREIGN COUNTRY <u>United Kingdom</u>	COUNTRY OF CITIZENSHIP <u>United Kingdom</u>
POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>University of Durham</u>	CITY <u>Durham</u>	STATE or COUNTRY <u>United Kingdom</u> ZIP CODE <u>DH1 3LE</u>
DATE <u>1 June 2005</u>	SIGNATURE OF INVENTOR <u>Ian Cummins</u>		
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	LAST NAME <u>EDWARDS</u>	FIRST NAME <u>ROBERT</u>	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY <u>Durham</u> <u>GBX</u>	STATE or FOREIGN COUNTRY <u>United Kingdom</u>	COUNTRY OF CITIZENSHIP <u>United Kingdom</u>
POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>University of Durham</u>	CITY <u>Durham</u>	STATE or COUNTRY <u>United Kingdom</u> ZIP CODE <u>DH1 3LE</u>
DATE <u>1 June 2005</u>	SIGNATURE OF INVENTOR <u>Robert Edwards</u>		
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY ZIP CODE
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY ZIP CODE
DATE	SIGNATURE OF INVENTOR		
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY ZIP CODE
DATE	SIGNATURE OF INVENTOR		

430 Rec'd PCT/PTO 15 MAR 2000

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: RHONE-POULENC AGRICULTURE LIMITED
- (B) STREET: FYFIELD ROAD
- (C) CITY: ONGAR
- (D) STATE: ESSEX
- (E) COUNTRY: UNITED KINGDOM
- (F) POSTAL CODE (ZIP): CM5 0HW

(ii) TITLE OF INVENTION: GLUTATHIONE TRANSFERASES

(iii) NUMBER OF SEQUENCES: 19

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0.
Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1085 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 46..711

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..1085
- (D) OTHER INFORMATION: /note= "SEQUENCE OF TaGST1 AND
ENCODED AMINO ACID SEQUENCE"

(x1) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CAAACACAAG CACAGATCGG TCGAGATTCA AGGCAACCGG GAGCA ATG GCG GGC	54
Met Ala Gly	
GAG AAG GGG CTG GTG CTG CTG GAC TTC TGG GTG AGC CCG TTC GGG CAG	102
Glu Lys Gly Leu Val Leu Leu Asp Phe Trp Val Ser Pro Phe Gly Gln	
CGC GTG CGC ATC GCG CTG GCC GAG AAG GGC CTG CCC TAC GAG TAC GCG	150
Arg Val Arg Ile Ala Leu Ala Glu Lys Gly Leu Pro Tyr Glu Tyr Ala	
GAG GAG GAC CTG ATG GCC GGC AAG AGC GAC CGC CTC CTC GCG GCC AAC	198
Glu Glu Asp Leu Met Ala Gly Lys Ser Asp Arg Leu Leu Arg Ala Asn	
CCG GTG CAT AAG AAG ATC CCG GTG CTC CTC CAC GAC GGC CGT GCC GTC	246
Pro Val His Lys Lys Ile Pro Val Leu Leu His Asp Gly Arg Ala Val	
AAC GAG TCC CTC ATC ATC CTC CAG TAC CTG GAG GAG GCC TTC CCG GAC	294
Asn Glu Ser Leu Ile Ile Leu Gln Tyr Leu Glu Glu Ala Phe Pro Asp	
GCG CCC GCT CTG CTC CCC TCC GAC CCC TAC GCG CGC GCG CAG GCC CGC	342
Ala Pro Ala Leu Leu Pro Ser Asp Pro Tyr Ala Arg Ala Gln Ala Arg	
TTC TGG GCC GAC TAC GTC GAC AAG AAG GTC TAC GAC TGC GGC TCC CGC	390
Phe Trp Ala Asp Tyr Val Asp Lys Lys Val Tyr Asp Cys Gly Ser Arg	
CTC TGG AAG CTC AAG GGC GAG CCG CAG GCG CAG GCG CGC GCC GAG ATG	438
Leu Trp Lys Leu Lys Gly Glu Pro Gln Ala Gln Ala Arg Ala Glu Met	
CTG GAC ATC CTC AAG ACC CTC GAC GGC GCG CTC GGG GAC AAG CCC TTC	486
Leu Asp Ile Leu Lys Thr Leu Asp Gly Ala Leu Gly Asp Lys Pro Phe	
TTC GGC GGC GAC AAG TTC GGG TTC GTC GAC GCC GCC TTC GCG CCC TTC	534
Phe Gly Gly Asp Lys Phe Gly Phe Val Asp Ala Ala Phe Ala Pro Phe	
ACC GCG TGG TTC CAC AGC TAC GAG AGG TAC GGC GAG TTC AGC CTG CCG	582
Thr Ala Trp Phe His Ser Tyr Glu Arg Tyr Gly Glu Phe Ser Leu Pro	
GAG GTG GCG CCC AAG ATC GCC GCG TGG GCC AAG CGC TGC GGC GAG CGG	630
Glu Val Ala Pro Lys Ile Ala Ala Trp Ala Lys Arg Cys Gly Glu Arg	
GAG AGC GTC GCC AAG AGC CTC TAC TCG CCG GAC AAG GTG TAC GAC TTC	678
Glu Ser Val Ala Lys Ser Leu Tyr Ser Pro Asp Lys Val Tyr Asp Phe	
ATC GGC CTG CTC AAG AAG AAG TAC GGC ATC GAG TA GCGCGCCGA	723
Ile Gly Leu Leu Lys Lys Lys Tyr Gly Ile Glu	

CGGACGGACG GACGGGCCAT GCAGGCGACA GCCGGCCCGC CGTCCGGAGG GAAGCAACAA 783
 ATAAATCAGG GAGCGATTG GGTGGCCTAC AATGCGTACG TCTGGATAGA GTATTCTTT 843
 CTTTCTTTCT TCGTGAATA AAGTGCTCCG TGTGTGTGTG GTTGGTGGTT GTTGGTTGGA 903
 TCAGTCAGTG TGTGTGGGTG CGTGTGTGTG ACTCAGTACT CGTGATGTGT GTGTGTGTCA 963
 ATGTGTCAAC CCTGGTCTTC GGTGGGGGCA GCACCGAGTT GCCACCTGCC ATTCATTTC1023
 CATTCCGGGC GATGAATAAA TTAAAAAGA GTCTCATTTG TTTAAAAAAA AAAAAAAAAA1083
 AA 1085

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 222 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met	Ala	Gly	Glu	Lys	Gly	Leu	Val	Leu	Leu	Asp	Phe	Trp	Val	Ser	Pro
1				5				10					15		
Phe	Gly	Gln	Arg	Val	Arg	Ile	Ala	Leu	Ala	Glu	Lys	Gly	Leu	Pro	Tyr
		20					25						30		
Glu	Tyr	Ala	Glu	Glu	Asp	Leu	Met	Ala	Gly	Lys	Ser	Asp	Arg	Leu	Leu
		35					40					45			
Arg	Ala	Asn	Pro	Val	His	Lys	Lys	Ile	Pro	Val	Leu	Leu	His	Asp	Gly
		50					55				60				
Arg	Ala	Val	Asn	Glu	Ser	Leu	Ile	Ile	Leu	Gln	Tyr	Leu	Glu	Glu	Ala
		65					70				75				80
Phe	Pro	Asp	Ala	Pro	Ala	Leu	Leu	Pro	Ser	Asp	Pro	Tyr	Ala	Arg	Ala
			85						90				95		
Gln	Ala	Arg	Phe	Trp	Ala	Asp	Tyr	Val	Asp	Lys	Lys	Val	Tyr	Asp	Cys
			100						105				110		

Gly Ser Arg Leu Trp Lys Leu Lys Gly Glu Pro Gln Ala Gln Ala Arg
 115 120 125

Ala Glu Met Leu Asp Ile Leu Lys Thr Leu Asp Gly Ala Leu Gly Asp
 130 135 140

Lys Pro Phe Phe Gly Gly Asp Lys Phe Gly Phe Val Asp Ala Ala Phe
 145 150 155 160

Ala Pro Phe Thr Ala Trp Phe His Ser Tyr Glu Arg Tyr Gly Glu Phe
 165 170 175

Ser Leu Pro Glu Val Ala Pro Lys Ile Ala Ala Trp Ala Lys Arg Cys
 180 185 190

Gly Glu Arg Glu Ser Val Ala Lys Ser Leu Tyr Ser Pro Asp Lys Val
 195 200 205

Tyr Asp Phe Ile Gly Leu Leu Lys Lys Lys Tyr Gly Ile Glu
 210 215 220

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 865 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:54..725

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..865
- (D) OTHER INFORMATION:/note= "WIC1 SEQUENCE AND ENCODED
 IC1 AMINO ACID SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GGAAGCTCAAC CATTGATCTT CAAGAAGCGG AAGCAAACAG AGCAAAAGGT GTG ATG
 Met

56

GCG GCG CCG GCG GTG AAG GTG TAC GGG TGG GCG ATG TCG CCG TTC GTG 104
 Ala Ala Pro Ala Val Lys Val Tyr Gly Trp Ala Met Ser Pro Phe Val
 GCG GCG GCG CTG CTG TGC CTG GAG GAG GCC GGC GTG GAG TAC GAG CTC 152
 Ala Arg Ala Leu Leu Cys Leu Glu Glu Ala Gly Val Glu Tyr Glu Leu
 GTC CCC ATG AGC CGC GAG GCC GGC GAC CAC CGC CAG CCC GAC TTC CTC 200
 Val Pro Met Ser Arg Glu Ala Gly Asp His Arg Gln Pro Asp Phe Leu
 GCC CGG AAC CCC TTC GGC CAG GTC CCC GTT CTC GAG GAC GGC GAC CTC 248
 Ala Arg Asn Pro Phe Gly Gln Val Pro Val Leu Glu Asp Gly Asp Leu
 ACC ATC TTC GAG TCG CGC GCC GTC GCG AGG CAC GTG CTG CGC AAG CAC 296
 Thr Ile Phe Glu Ser Arg Ala Val Ala Arg His Val Leu Arg Lys His
 AAA CCG GAG CTG CTG GGC TCC GGC TCG CCG GAG TCG GCG GCG ATG GTG 344
 Lys Pro Glu Leu Leu Gly Ser Gly Ser Pro Glu Ser Ala Ala Met Val
 GAC GTG TGG CTG GAG GTG GAG GCC CAC CAG CAC CAG ACC CCG GCG GGC 392
 Asp Val Trp Leu Glu Val Glu Ala His Gln His Gln Thr Pro Ala Gly
 ACC ATC GTC ATG CAG TGC ATC CTC ACC CCG TTC CTC GGC TGC CAG CGC 440
 Thr Ile Val Met Gln Cys Ile Leu Thr Pro Phe Leu Gly Cys Gln Arg
 GAC CAG GCC GCC ATC GAC GAG AAC GCG GCA AAG CTG ACG AAT CTG TTC 488
 Asp Gln Ala Ala Ile Asp Glu Asn Ala Ala Lys Leu Thr Asn Leu Phe
 GAC GTG TAC GAG GCG CGC CTG TCG GCG TCG AGG TAC CTT GCC GGG GAG 536
 Asp Val Tyr Glu Ala Arg Leu Ser Ala Ser Arg Tyr Leu Ala Gly Glu
 GCG GTC AGC CTC GCG GAC CTC AGC CAC TTC CCG TTC ATG CGA TAC TTC 584
 Ala Val Ser Leu Ala Asp Leu Ser His Phe Pro Phe Met Arg Tyr Phe
 ATG GAC ACC GAG TAC GCG TCG CTG GTG GAG GAG CGC CCG CAC GTG AAG 632
 Met Asp Thr Glu Tyr Ala Ser Leu Val Glu Glu Arg Pro His Val Lys
 GCG TGG TGG GAG GAG TTC AAG GCC AGC CCG GCG GCG AAG AGG GTG ACG 680
 Ala Trp Trp Glu Glu Phe Lys Ala Ser Pro Ala Ala Lys Arg Val Thr
 GAG TTC ATG CCG CCA AAC TTC GGG TTC GGA AAG AAG GCA GAG AAG 725
 Glu Phe Met Pro Pro Asn Phe Gly Phe Gly Lys Lys Ala Glu Lys
 TGATGACAAG AACGAACACC GAGCGAACAT GTTGTGTGGT CTGTGCGACC CGACCATGGC 785
 TCAATGTTTT GGGCTGTTTG TGTTTCACGC ATGAATGAAT AAAACAAAAT GCTTTTGGGT 845

TTCAAAAAA AAAAAAAAAA

865

(2) INFORMATION FOR SEQ ID NO: 4:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 224 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```

Met Ala Ala Pro Ala Val Lys Val Tyr Gly Trp Ala Met Ser Pro Phe
 1             5             10             15

Val Ala Arg Ala Leu Leu Cys Leu Glu Glu Ala Gly Val Glu Tyr Glu
          20             25             30

Leu Val Pro Met Ser Arg Glu Ala Gly Asp His Arg Gln Pro Asp Phe
          35             40             45

Leu Ala Arg Asn Pro Phe Gly Gln Val Pro Val Leu Glu Asp Gly Asp
          50             55             60

Leu Thr Ile Phe Glu Ser Arg Ala Val Ala Arg His Val Leu Arg Lys
          65             70             75             80

His Lys Pro Glu Leu Leu Gly Ser Gly Ser Pro Glu Ser Ala Ala Met
          85             90             95

Val Asp Val Trp Leu Glu Val Glu Ala His Gln His Gln Thr Pro Ala
          100            105            110

Gly Thr Ile Val Met Gln Cys Ile Leu Thr Pro Phe Leu Gly Cys Gln
          115            120            125

Arg Asp Gln Ala Ala Ile Asp Glu Asn Ala Ala Lys Leu Thr Asn Leu
          130            135            140

Phe Asp Val Tyr Glu Ala Arg Leu Ser Ala Ser Arg Tyr Leu Ala Gly
          145            150            155            160

Glu Ala Val Ser Leu Ala Asp Leu Ser His Phe Pro Phe Met Arg Tyr
          165            170            175

```

Phe Met Asp Thr Glu Tyr Ala Ser Leu Val Glu Glu Arg Pro His Val
180 185 190

Lys Ala Trp Trp Glu Glu Phe Lys Ala Ser Pro Ala Ala Lys Arg Val
195 200 205

Thr Glu Phe Met Pro Pro Asn Phe Gly Phe Gly Lys Lys Ala Glu Lys
210 215 220

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 930 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:60..725

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..930
- (D) OTHER INFORMATION:/note= "WIC2 SEQUENCE AND ENCODED
IC2 AMINO ACID SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

```

CACGCGTCCA TCTCCAAGAA GCGGAAGCTA GTGGAGCAGA GCAAACCAAG CAAGGTTGG   59
ATG GCG CCG GCG GTG AAG GTG TAC GGG TGG GCC GTG TCG CCG TTC GTG   107
Met Ala Pro Ala Val Lys Val Tyr Gly Trp Ala Val Ser Pro Phe Val
GCG CGC CCA CTG CTG TGC CTG GAG GAG GCC GGC GTC GAG TAC GAG CTC   155
Ala Arg Pro Leu Leu Cys Leu Glu Glu Ala Gly Val Glu Tyr Glu Leu
GTG TCC ATG AGC CGC GCG GCC GGC GAC CAC CGC CAG CCG GAC TTC CTC   203
Val Ser Met Ser Arg Ala Ala Gly Asp His Arg Gln Pro Asp Phe Leu
GCC CGG AAC CCC TTC GGC CAG GTC CCC GTC CTC GAG GAC GGC GAC CTC   251
Ala Arg Asn Pro Phe Gly Gln Val Pro Val Leu Glu Asp Gly Asp Leu

```

ACC CTC TTC GAG TCG CGC GCG ATC GCG AGG CAC GTG CTC CGG AAG CAC 299
 Thr Leu Phe Glu Ser Arg Ala Ile Ala Arg His Val Leu Arg Lys His

 AAG CCG GAG CTG CTG GGC TGC GGC TCG CCG GAG GCG GAG GCG ATG GTG 347
 Lys Pro Glu Leu Leu Gly Cys Gly Ser Pro Glu Ala Glu Ala Met Val

 GAC GTG TGG CTG GAG GTG GAG GCC CAC CAG TAC AAC CCC GCG GCC AGC 395
 Asp Val Trp Leu Glu Val Glu Ala His Gln Tyr Asn Pro Ala Ala Ser

 GCC ATC GTG GTG CAG TGC ATC ATC TTG CCG CTA CTG GGC GGC GCG CGG 443
 Ala Ile Val Val Gln Cys Ile Ile Leu Pro Leu Leu Gly Gly Ala Arg

 GAC CAG GCG GTG GTG GAC GAG AAC GTA GCC AAG CTC AAG AAG GTG CTG 491
 Asp Gln Ala Val Val Asp Glu Asn Val Ala Lys Leu Lys Lys Val Leu

 GAG GTG TAC GAG GCA CGG CTG TCG GCG TCC AGG TAC CTC GCC GGG GAC 539
 Glu Val Tyr Glu Ala Arg Leu Ser Ala Ser Arg Tyr Leu Ala Gly Asp

 GAC ATC AGC CTC GCC GAC CTC AGC CAC TTC CCC TTC ACG CGC TAC TTC 587
 Asp Ile Ser Leu Ala Asp Leu Ser His Phe Pro Phe Thr Arg Tyr Phe

 ATG GAG ACG GAG TAC GCG CCG CTG GTG GCG GAG CTC CCC CAC GTG AAC 635
 Met Glu Thr Glu Tyr Ala Pro Leu Val Ala Glu Leu Pro His Val Asn

 GCG TGG TGG GAG GGG CTC AAG GCC AGG CCG GCC GCG AGG AAG GTG ACG 683
 Ala Trp Trp Glu Gly Leu Lys Ala Arg Pro Ala Ala Arg Lys Val Thr

 GAG CTC ATG CCG CCG GAC CTT GGG CTT GGA AAG AAA GCA GAG 725
 Glu Leu Met Pro Pro Asp Leu Gly Leu Gly Lys Lys Ala Glu

 TAGTGATGAC TGCCGCCAAC GTTCACCAGG ATCGAGCAAG TCACTGTCGA GTCTCCGGTT 785
 TTGCGTTGTA CGGCACCGGG GCACCGGCCT ATATTTTCTG TACCAAGTGGC TCGTGTTTTG 845
 ATGTTTTAGT CTCACGCTTG AATAAAATGC AAGATATACC CATCGTTTCT AAAAGAAAAA 905
 AAAAAAAAAA AAAAAAAAAA AAAAA 930

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 222 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

```

Met Ala Pro Ala Val Lys Val Tyr Gly Trp Ala Val Ser Pro Phe Val
 1           5           10           15
Ala Arg Pro Leu Leu Cys Leu Glu Glu Ala Gly Val Glu Tyr Glu Leu
          20           25           30
Val Ser Met Ser Arg Ala Ala Gly Asp His Arg Gln Pro Asp Phe Leu
          35           40           45
Ala Arg Asn Pro Phe Gly Gln Val Pro Val Leu Glu Asp Gly Asp Leu
          50           55           60
Thr Leu Phe Glu Ser Arg Ala Ile Ala Arg His Val Leu Arg Lys His
          65           70           75           80
Lys Pro Glu Leu Leu Gly Cys Gly Ser Pro Glu Ala Glu Ala Met Val
          85           90           95
Asp Val Trp Leu Glu Val Glu Ala His Gln Tyr Asn Pro Ala Ala Ser
          100          105          110
Ala Ile Val Val Gln Cys Ile Ile Leu Pro Leu Leu Gly Gly Ala Arg
          115          120          125
Asp Gln Ala Val Val Asp Glu Asn Val Ala Lys Leu Lys Lys Val Leu
          130          135          140
Glu Val Tyr Glu Ala Arg Leu Ser Ala Ser Arg Tyr Leu Ala Gly Asp
          145          150          155          160
Asp Ile Ser Leu Ala Asp Leu Ser His Phe Pro Phe Thr Arg Tyr Phe
          165          170          175
Met Glu Thr Glu Tyr Ala Pro Leu Val Ala Glu Leu Pro His Val Asn
          180          185          190
Ala Trp Trp Glu Gly Leu Lys Ala Arg Pro Ala Ala Arg Lys Val Thr
          195          200          205
Glu Leu Met Pro Pro Asp Leu Gly Leu Gly Lys Lys Ala Glu
          210          215          220

```

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 927 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 72..707

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 1..927
 (D) OTHER INFORMATION: /note= "WIC 3/7/8 SEQUENCE AND
 ENCODED IC3 AMINO ACID SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

```

AGCGGCTTTA CCTACCGAGA AGAAGAGAGA AAAAAGGTTT GAGTGC GTTC CAGAGTGAGG 60
AGTGAGAAGA G ATG GCT CCG GTG AAG CTG TAC GGC GCG ACC CTG TCG TGG 110
      Met Ala Pro Val Lys Leu Tyr Gly Ala Thr Leu Ser Trp
AAC GTC ACC AGG TGC GTG GCG GCG CTG GAG GAG GCC GGC GTC CAG TAC 158
Asn Val Thr Arg Cys Val Ala Ala Leu Glu Glu Ala Gly Val Gln Tyr
GAG ATC GTA CCC ATC AAC TTC GGC ACC GGC GAG CAC AAG AGC CCC GAC 206
Glu Ile Val Pro Ile Asn Phe Gly Thr Gly Glu His Lys Ser Pro Asp
CAC CTC GCC AGG AAC CCC TTC GGC CAG GTG CCA GCT TTG CAG GAT GGT 254
His Leu Ala Arg Asn Pro Phe Gly Gln Val Pro Ala Leu Gln Asp Gly
GAC TTA TAC GTC TTC GAA TCA CGT GCT ATT TGC AAG TAC GCG TGC CGC 302
Asp Leu Tyr Val Phe Glu Ser Arg Ala Ile Cys Lys Tyr Ala Cys Arg
AAG AAC AAG CCA GAG CTG TTG AAG GAG GGC GAC ATC AAG GAG TCA GCA 350
Lys Asn Lys Pro Glu Leu Leu Lys Glu Gly Asp Ile Lys Glu Ser Ala
ATG GTG GAT GTG TGG CTC GAG GTG GAG GCC CAT CAG TAC ACT GCC GCT 398
Met Val Asp Val Trp Leu Glu Val Glu Ala His Gln Tyr Thr Ala Ala
CTG AGC CCC ATT CTC TTC GAG TGC CTT ATC CAT CCA ATG CTT GGG GGA 446
Leu Ser Pro Ile Leu Phe Glu Cys Leu Ile His Pro Met Leu Gly Gly

```

GCC ACT GAC CAG AAG GTC ATC GAC GAC AAC CTT GTT AAG ATC AAG AAC 494
 Ala Thr Asp Gln Lys Val Ile Asp Asp Asn Leu Val Lys Ile Lys Asn

GTG CTG GCG GTG TAC GAG GCG CAC CTG AGC AAG TCC AAG TAC CTG GCT 542
 Val Leu Ala Val Tyr Glu Ala His Leu Ser Lys Ser Lys Tyr Leu Ala

GGA GAC TTC CTC AGT CTT GCG GAC CTT AAC CAT GTG TCT GTC ACC CTG 590
 Gly Asp Phe Leu Ser Leu Ala Asp Leu Asn His Val Ser Val Thr Leu

TGC TTG GCG GCT ACA CCC TAT GCG TCT CTG TTC GAC GCG TAC CCG CAT 638
 Cys Leu Ala Ala Thr Pro Tyr Ala Ser Leu Phe Asp Ala Tyr Pro His

GTG AAG GCC TGG TGG ACT GAC CTG CTG GCG AGG CCG TCC GTC CAG AAG 686
 Val Lys Ala Trp Trp Thr Asp Leu Leu Ala Arg Pro Ser Val Gln Lys

GTC GCA GCG CTG ATG AAG CCA TGATCTTAAT TGCTGGTGCT CGTTCGTCGC 737
 Val Ala Ala Leu Met Lys Pro

GAAATAAGCC GAGGTGTGTG CCCCCGATG TGTGCCTGTA CGAGTGTGTG TTCTTGAT 797
 GTCTCCTCGT GTTGAATGTT CAGGCTTGTG CTTGCGATCC TGTCATCATCT TTTACTGAAA 857
 TGAGCGTTCC TATGCTCTGG TTTAATAATA AATTGTGCCT AGATATTATC TCAAAAAAAA 917
 AAAAAAAAAA 927

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 212 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met	Ala	Pro	Val	Lys	Leu	Tyr	Gly	Ala	Thr	Leu	Ser	Trp	Asn	Val	Thr
1				5					10					15	
Arg	Cys	Val	Ala	Ala	Leu	Glu	Glu	Ala	Gly	Val	Gln	Tyr	Glu	Ile	Val
			20					25					30		
Pro	Ile	Asn	Phe	Gly	Thr	Gly	Glu	His	Lys	Ser	Pro	Asp	His	Leu	Ala
		35					40						45		

Arg Asn Pro Phe Gly Gln Val Pro Ala Leu Gln Asp Gly Asp Leu Tyr
50 55 60

Val Phe Glu Ser Arg Ala Ile Cys Lys Tyr Ala Cys Arg Lys Asn Lys
65 70 75 80

Pro Glu Leu Leu Lys Glu Gly Asp Ile Lys Glu Ser Ala Met Val Asp
85 90 95

Val Trp Leu Glu Val Glu Ala His Gln Tyr Thr Ala Ala Leu Ser Pro
100 105 110

Ile Leu Phe Glu Cys Leu Ile His Pro Met Leu Gly Gly Ala Thr Asp
115 120 125

Gln Lys Val Ile Asp Asp Asn Leu Val Lys Ile Lys Asn Val Leu Ala
130 135 140

Val Tyr Glu Ala His Leu Ser Lys Ser Lys Tyr Leu Ala Gly Asp Phe
145 150 155 160

Leu Ser Leu Ala Asp Leu Asn His Val Ser Val Thr Leu Cys Leu Ala
165 170 175

Ala Thr Pro Tyr Ala Ser Leu Phe Asp Ala Tyr Pro His Val Lys Ala
180 185 190

Trp Trp Thr Asp Leu Leu Ala Arg Pro Ser Val Gln Lys Val Ala Ala
195 200 205

Leu Met Lys Pro
210

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 866 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS

(B) LOCATION:45..683

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION:1..866

(D) OTHER INFORMATION:/note= "WIC5 SEQUENCE AND ENCODED
IC5 AMINO ACID SEQUENCE"

(x1) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GAAGCAGGCA ACAGGCGAGC AGGAAGGAAG CAAGAGAGGT GGAG ATG GCG CCC ATC	56
Met Ala Pro Ile	
AAG CTG TAC GGG ATG ATG CTG TCG GCC AAC GTG ACC CGC GTG ACC ACG	104
Lys Leu Tyr Gly Met Met Leu Ser Ala Asn Val Thr Arg Val Thr Thr	
CTG CTC AAC GAG CTC GGC CTC GAG TTC GAC TTC GTC GAC GTC GAC CTC	152
Leu Leu Asn Glu Leu Gly Leu Glu Phe Asp Phe Val Asp Val Asp Leu	
CGC ACC GGC GCC CAC AAG CAC CCC GAC TTC CTC AAG CTC AAC CCT TTC	200
Arg Thr Gly Ala His Lys His Pro Asp Phe Leu Lys Leu Asn Pro Phe	
GGC CAG ATC CCC GCG CTG CAG GAC GGA GAC GAA GTT GTC TTC GAG TCG	248
Gly Gln Ile Pro Ala Leu Gln Asp Gly Asp Glu Val Val Phe Glu Ser	
CGC GCC ATC AAC CGG TAC ATC GCG ACC AAG TAC GGG GCG TCC CTG CTG	296
Arg Ala Ile Asn Arg Tyr Ile Ala Thr Lys Tyr Gly Ala Ser Leu Leu	
CCG ACG CCG TCG GCC AAG CTG GAG GCG TGG CTG GAG GTG GAG TCG CAC	344
Pro Thr Pro Ser Ala Lys Leu Glu Ala Trp Leu Glu Val Glu Ser His	
CAC TTC TAC CCG CCG GCG CGG ACG CTG GTG TAC GAG CTG GTC ATC AAG	392
His Phe Tyr Pro Pro Ala Arg Thr Leu Val Tyr Glu Leu Val Ile Lys	
CCC ATG CTG GGC GCC CCC ACC GAC GCC GCC GAG GTG GAC AAG AAC GCC	440
Pro Met Leu Gly Ala Pro Thr Asp Ala Ala Glu Val Asp Lys Asn Ala	
GCC GAC CTC GCC AAG CTG CTC GAC GTC TAC GAG GCC CAC CTC GCC GCC	488
Ala Asp Leu Ala Lys Leu Leu Asp Val Tyr Glu Ala His Leu Ala Ala	
GGG AAC AAG TAC CTG GCC GGC GAC GCC TTC CCG CTC GCC GAC GCC AAC	536
Gly Asn Lys Tyr Leu Ala Gly Asp Ala Phe Pro Leu Ala Asp Ala Asn	
CAC ATG TCC TAC CTC TTC ATG CTC ACC AAG AGC CCC AAG GCG GAC CTG	584
His Met Ser Tyr Leu Phe Met Leu Thr Lys Ser Pro Lys Ala Asp Leu	

GTG GCC TCC CGC CCG CAC GTC AAG GCC TGG TGG GAG GAG ATC TCC GCC 632
Val Ala Ser Arg Pro His Val Lys Ala Trp Trp Glu Glu Ile Ser Ala

CGC CCC GCC TGG GCC AAG ACC GTC GCC TCC ATC CCC CTC CCG CCC GCC 680
Arg Pro Ala Trp Ala Lys Thr Val Ala Ser Ile Pro Leu Pro Pro Ala

GTC TGAGGTTGCT TGTTTGGCTG CGGCGAGAAC GGAATAAAAT CGCGATGATG 733
Val

GAATAAACAA CTTTTAGAG AGGAAGCTTG GAATCTTGG TGTGCTGCT GTTGAATGTT 793

GAATCTTGTT GTTGAATGTT TACGGCACAT CTAATTTATC CAGTTTTTTT GCGTGAAAA 853

AAAAAAAAAA AAA 866

(2) INFORMATION FOR SEQ ID NO: 10.

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 213 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Met Ala Pro Ile Lys Leu Tyr Gly Met Met Leu Ser Ala Asn Val Thr
1 5 10 15

Arg Val Thr Thr Leu Leu Asn Glu Leu Gly Leu Glu Phe Asp Phe Val
20 25 30

Asp Val Asp Leu Arg Thr Gly Ala His Lys His Pro Asp Phe Leu Lys
35 40 45

Leu Asn Pro Phe Gly Gln Ile Pro Ala Leu Gln Asp Gly Asp Glu Val
50 55 60

Val Phe Glu Ser Arg Ala Ile Asn Arg Tyr Ile Ala Thr Lys Tyr Gly
65 70 75 80

Ala Ser Leu Leu Pro Thr Pro Ser Ala Lys Leu Glu Ala Trp Leu Glu
85 90 95

Val Glu Ser His His Phe Tyr Pro Pro Ala Arg Thr Leu Val Tyr Glu
100 105 110

Leu Val Ile Lys Pro Met Leu Gly Ala Pro Thr Asp Ala Ala Glu Val
115 120 125

Asp Lys Asn Ala Ala Asp Leu Ala Lys Leu Leu Asp Val Tyr Glu Ala
130 135 140

His Leu Ala Ala Gly Asn Lys Tyr Leu Ala Gly Asp Ala Phe Pro Leu
145 150 155 160

Ala Asp Ala Asn His Met Ser Tyr Leu Phe Met Leu Thr Lys Ser Pro
165 170 175

Lys Ala Asp Leu Val Ala Ser Arg Pro His Val Lys Ala Trp Trp Glu
180 185 190

Glu Ile Ser Ala Arg Pro Ala Trp Ala Lys Thr Val Ala Ser Ile Pro
195 200 205

Leu Pro Pro Ala Val
210

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 897 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:15..668

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..897
- (D) OTHER INFORMATION:/note= "WIC4 SEQUENCE AND ENCODED IC4 AMINO ACID SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

AACCAAGGGA AACA ATG GCG CCG GTG AAG GTG TTC GGG CCG GCG ATG TCG 50

Met Ala Pro Val Lys Val Phe Gly Pro Ala Met Ser

ACC AAC GTG GCC CGG GTG CTG GTG TGC CTG GAG GAG GTC GGC GCC GAG 98
 Thr Asn Val Ala Arg Val Leu Val Cys Leu Glu Glu Val Gly Ala Glu

TAC GAG GTG GTC GAC ATC GAT TTC AAG GCC ATG GAG CAC AAG AGC CCC 146
 Tyr Glu Val Val Asp Ile Asp Phe Lys Ala Met Glu His Lys Ser Pro

GAG CAT CTC GTC AGA AAC CCG TTC GGC CAA ATC CCT GCC TTC CAG GAT 194
 Glu His Leu Val Arg Asn Pro Phe Gly Gln Ile Pro Ala Phe Gln Asp

GGG GAT CTG CTT CTC TTC GAG TCA CGC GCA ATT GCG AGG TAC GTG CTC 242
 Gly Asp Leu Leu Leu Phe Glu Ser Arg Ala Ile Ala Arg Tyr Val Leu

CGC AAG TAC AAG AAG AAC GAA GTG GAC CTG CTG AGG GAA GGC GAC CTC 290
 Arg Lys Tyr Lys Lys Asn Glu Val Asp Leu Leu Arg Glu Gly Asp Leu

AAG GAG GCG GCG ATG GTG GAC GTA TGG ACG GAG GTG GAC GCG CAC ACC 338
 Lys Glu Ala Ala Met Val Asp Val Trp Thr Glu Val Asp Ala His Thr

TAC AAC CCG GCC ATC TCG CCG ATC GTG TAC GAG TGC TCA TCA ACC GCT 386
 Tyr Asn Pro Ala Ile Ser Pro Ile Val Tyr Glu Cys Ser Ser Thr Ala

CAT GCG CGG CTG CCG ACC AAC CAA ACG GTG GTG GAC GAG AGC CTG GAG 434
 His Ala Arg Leu Pro Thr Asn Gln Thr Val Val Asp Glu Ser Leu Glu

AAG CTC AAG AAC GTG CTG GAG GTC TAC GAG GCG CGC CTG TCC AAG CAC 482
 Lys Leu Lys Asn Val Leu Glu Val Tyr Glu Ala Arg Leu Ser Lys His

GAC TAC CTC GCC GGG GAC TTC GTC AGC TTC GCG GAC CTC AAC CAC TTC 530
 Asp Tyr Leu Ala Gly Asp Phe Val Ser Phe Ala Asp Leu Asn His Phe

CCC TAC ACC TTC TAC TTC ATG GCC ACG CCG CAC GCG GCC CTC TTC GAC 578
 Pro Tyr Thr Phe Tyr Phe Met Ala Thr Pro His Ala Ala Leu Phe Asp

TCG TAC CCG CAC GTC AAG GCC TGG TGG GAG AGG ATC ATG GCG AGG CCG 626
 Ser Tyr Pro His Val Lys Ala Trp Trp Glu Arg Ile Met Ala Arg Pro

GCC GTG AAG AAG CTC GCC GCG CAG ATG GTT CCC AAG AAG CCG 668
 Ala Val Lys Lys Leu Ala Ala Gln Met Val Pro Lys Lys Pro

TGATTTGCTA GGCGGGATCT CGCATCGTGG GATCCGATTC CGATCACTGA TCTGTGTGGC 728

GTTTTCTTTT CTGTGTGGTG TCGCGAATAA GGCAATGAG CTCGTGTGTG TGTGGCTGGA 788

ATTGCACCGA CGTGCAGTTT TTGCGCTTTG CGTGTGTGTG GTCGTGAAAA CTCTTGAGAT 848

53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

GGAACAATGT CTCGTAATG CTTTCACATT TTAACAAAAA AAAAAAAA

897

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 218 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Met	Ala	Pro	Val	Lys	Val	Phe	Gly	Pro	Ala	Met	Ser	Thr	Asn	Val	Ala	1	5	10	15
Arg	Val	Leu	Val	Cys	Leu	Glu	Glu	Val	Gly	Ala	Glu	Tyr	Glu	Val	Val	20	25	30	
Asp	Ile	Asp	Phe	Lys	Ala	Met	Glu	His	Lys	Ser	Pro	Glu	His	Leu	Val	35	40	45	
Arg	Asn	Pro	Phe	Gly	Gln	Ile	Pro	Ala	Phe	Gln	Asp	Gly	Asp	Leu	Leu	50	55	60	
Leu	Phe	Glu	Ser	Arg	Ala	Ile	Ala	Arg	Tyr	Val	Leu	Arg	Lys	Tyr	Lys	65	70	75	80
Lys	Asn	Glu	Val	Asp	Leu	Leu	Arg	Glu	Gly	Asp	Leu	Lys	Glu	Ala	Ala	85	90	95	
Met	Val	Asp	Val	Trp	Thr	Glu	Val	Asp	Ala	His	Thr	Tyr	Asn	Pro	Ala	100	105	110	
Ile	Ser	Pro	Ile	Val	Tyr	Glu	Cys	Ser	Ser	Thr	Ala	His	Ala	Arg	Leu	115	120	125	
Pro	Thr	Asn	Gln	Thr	Val	Val	Asp	Glu	Ser	Leu	Glu	Lys	Leu	Lys	Asn	130	135	140	
Val	Leu	Glu	Val	Tyr	Glu	Ala	Arg	Leu	Ser	Lys	His	Asp	Tyr	Leu	Ala	145	150	155	160
Gly	Asp	Phe	Val	Ser	Phe	Ala	Asp	Leu	Asn	His	Phe	Pro	Tyr	Thr	Phe	165	170	175	
Tyr	Phe	Met	Ala	Thr	Pro	His	Ala	Ala	Leu	Phe	Asp	Ser	Tyr	Pro	His				

180

185

190

Val Lys Ala Trp Trp Glu Arg Ile Met Ala Arg Pro Ala Val Lys Lys
 195 200 205

Leu Ala Ala Gln Met Val Pro Lys Lys Pro
 210 215

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 721 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 21..686

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..721
- (D) OTHER INFORMATION: /note= "TA 27 SEQUENCE AND ENCODED AMINO ACID SEQUENCE"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

TTCGGCACGA GGAAGAAGGG ATG GAG CCT ATG AAG GTG TAC GGC TGG GCG	50
Met Glu Pro Met Lys Val Tyr Gly Trp Ala	
GTG TCG CCA TGG ATG GCG CGG GTC CTC GTC TCC CTG GAG GAG GCC GGC	98
Val Ser Pro Trp Met Ala Arg Val Leu Val Ser Leu Glu Glu Ala Gly	
GCC GAC TAC GAG CTC GTG CCC ATG AGC CGC AAC GGC GGC GAC CAC CGG	146
Ala Asp Tyr Glu Leu Val Pro Met Ser Arg Asn Gly Gly Asp His Arg	
CGG CCG GAG CAC CTC GCC AGA AAC CCC TTC GGT GAG ATC CCG GTG CTC	194
Arg Pro Glu His Leu Ala Arg Asn Pro Phe Gly Glu Ile Pro Val Leu	
GAA TAC GGC GGT CTG ACG CTT TAC CAA TCC CGC GCC ATT GCA AGG CAT	242
Glu Tyr Gly Gly Leu Thr Leu Tyr Gln Ser Arg Ala Ile Ala Arg His	

ATT CTC CGC AAA CAC AAG CCC GGG CTT CTA GGA GCA GGC AGC CTC GAG 290
Ile Leu Arg Lys His Lys Pro Gly Leu Leu Gly Ala Gly Ser Leu Glu

GAG TCG GCG ATG GTG GAT GTA TGG GTC GAC GTG GAT GCC CAC CAC CTG 338
Glu Ser Ala Met Val Asp Val Trp Val Asp Val Asp Ala His His Leu

GAG CCC GTA CTC AAG CCC ATC GTG TGG AAC TGC ATC ATC AAC CCG TTC 386
Glu Pro Val Leu Lys Pro Ile Val Trp Asn Cys Ile Ile Asn Pro Phe

GTC GGG AGG GAC GTC GAC CAG GGC CTC GTC GAT GAG AGC GTC GAG AAG 434
Val Gly Arg Asp Val Asp Gln Gly Leu Val Asp Glu Ser Val Glu Lys

CTC AAG AAG CTG CTG GAG GTG TAC GAG GCA AGA CTG TCA AGC AAC AAG 482
Leu Lys Lys Leu Leu Glu Val Tyr Glu Ala Arg Leu Ser Ser Asn Lys

TAC TTG GCC GGG GAT TTC GTC AGC TTC GCC GAC CTC ACC CAT TTC TCC 530
Tyr Leu Ala Gly Asp Phe Val Ser Phe Ala Asp Leu Thr His Phe Ser

TTC ATG CGC TAC TTC ATG GCG ACG GAG CAT GCG GTT GTG CTC GAT GCG 578
Phe Met Arg Tyr Phe Met Ala Thr Glu His Ala Val Val Leu Asp Ala

TAT CCG CAT GTG AAG GCA TGG TGG AAG GCG CTG CTG GCA AGG CCA TCG 626
Tyr Pro His Val Lys Ala Trp Trp Lys Ala Leu Leu Ala Arg Pro Ser

GTC AAG AAG GTG ATA GCT GGC ATG CCT CCG GAT TTT GGA TTC GGG AGC 674
Val Lys Lys Val Ile Ala Gly Met Pro Pro Asp Phe Gly Phe Gly Ser

GGG AGA ATA CCA TGATAAAGCA TGCTTGTTTG TCTATGATGC TCTGA 721
Gly Arg Ile Pro

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 222 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Met Glu Pro Met Lys Val Tyr Gly Trp Ala Val Ser Pro Trp Met Ala
1 5 10 15

Arg Val Leu Val Ser Leu Glu Glu Ala Gly Ala Asp Tyr Glu Leu Val
20 25 30

Pro Met Ser Arg Asn Gly Gly Asp His Arg Arg Pro Glu His Leu Ala
 35 40 45
 Arg Asn Pro Phe Gly Glu Ile Pro Val Leu Glu Tyr Gly Gly Leu Thr
 50 55 60
 Leu Tyr Gln Ser Arg Ala Ile Ala Arg His Ile Leu Arg Lys His Lys
 65 70 75 80
 Pro Gly Leu Leu Gly Ala Gly Ser Leu Glu Glu Ser Ala Met Val Asp
 85 90 95
 Val Trp Val Asp Val Asp Ala His His Leu Glu Pro Val Leu Lys Pro
 100 105 110
 Ile Val Trp Asn Cys Ile Ile Asn Pro Phe Val Gly Arg Asp Val Asp
 115 120 125 -
 Gln Gly Leu Val Asp Glu Ser Val Glu Lys Leu Lys Lys Leu Leu Glu
 130 135 140
 Val Tyr Glu Ala Arg Leu Ser Ser Asn Lys Tyr Leu Ala Gly Asp Phe
 145 150 155 160
 Val Ser Phe Ala Asp Leu Thr His Phe Ser Phe Met Arg Tyr Phe Met
 165 170 175
 Ala Thr Glu His Ala Val Val Leu Asp Ala Tyr Pro His Val Lys Ala
 180 185 190
 Trp Trp Lys Ala Leu Leu Ala Arg Pro Ser Val Lys Lys Val Ile Ala
 195 200 205
 Gly Met Pro Pro Asp Phe Gly Phe Gly Ser Gly Arg Ile Pro
 210 215 220

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 926 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(1x) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:66..764

(x1) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

AACCACTTTC ATCAACGTCT CCTACGCTCA CCGTTCGTTG CTCGACAT CAGCAGGACT 60

TGCCA ATG GCG GGA GAC GGC GAG CTG AAG CTG CTG GGC GTG TGG ACG 107
Met Ala Gly Asp Gly Glu Leu Lys Leu Leu Gly Val Trp Thr
1 5 10

AGC CCG TTC GTC ATC AGG GTG CGC GTG GTG CTC AAC CTC AAG TCG CTG 155
Ser Pro Phe Val Ile Arg Val Arg Val Val Leu Asn Leu Lys Ser Leu
15 20 25 30

CCG TAC GAG TAC GTG GAG GAG AGC CTG GGC AGC AAG AGC GCG CTC CTC 203
Pro Tyr Glu Tyr Val Glu Glu Ser Leu Gly Ser Lys Ser Ala Leu Leu
35 40 45

CTG GGC TCC AAC CCG GTG CAC CAG AGC GTG CCC GTC CTC CTC CAC GGC 251
Leu Gly Ser Asn Pro Val His Gln Ser Val Pro Val Leu Leu His Gly
50 55 60

GGC CGC CCC GTG AAC GAG TCC CAG GTC ATC GTG CAG TAC ATC GAC GAG 299
Gly Arg Pro Val Asn Glu Ser Gln Val Ile Val Gln Tyr Ile Asp Glu
65 70 75

GTC TGG GCG GGG GCC GGC CCG TCC GTG CTC CCG GCC GAC CCC TAC GAG 347
Val Trp Ala Gly Ala Gly Pro Ser Val Leu Pro Ala Asp Pro Tyr Glu
80 85 90

CGC GCC ACG GCG CGC TTC TGG GCG GCG TAC GTC GAC GAC AAG GTC GGG 395
Arg Ala Thr Ala Arg Phe Trp Ala Ala Tyr Val Asp Asp Lys Val Gly
95 100 105 110

TCG GCG TGG ACG GGG ATG CTC TTC TCG TGC AAG ACG GAG GAG GAG CGG 443
Ser Ala Trp Thr Gly Met Leu Phe Ser Cys Lys Thr Glu Glu Glu Arg
115 120 125

GCG GAG GCG GTG TCC CGG GCC GTG GCG GCG CTG GAG ACC CTG GAG GGC 491
Ala Glu Ala Val Ser Arg Ala Val Ala Ala Leu Glu Thr Leu Glu Gly
130 135 140

```

GCG TTC GCG GAG TGC TCC AAG GGG AAG GCG TTC TTC GGC GGC GAC GCC 539
Ala Phe Ala Glu Cys Ser Lys Gly Lys Ala Phe Phe Gly Gly Asp Ala
      145                      150                      155

ATC GGG TTC GTC GAC GTC GTG CTT GGC GGC TAC CTC GGC TGG TTC GGC 587
Ile Gly Phe Val Asp Val Val Leu Gly Gly Tyr Leu Gly Trp Phe Gly
      160                      165                      170

GCG ATC GAC AAG ATC ATC GGG CGC CGG CTG ATC GAC CCG GCG AGG ACG 635
Ala Ile Asp Lys Ile Ile Gly Arg Arg Leu Ile Asp Pro Ala Arg Thr
      175                      180                      185                      190

CCG CTG CTG GCC AGG TGG GAG GAG CGG TTC CGC GCG GCG GAC GCG GCC 683
Pro Leu Leu Ala Arg Trp Glu Glu Arg Phe Arg Ala Ala Asp Ala Ala
      195                      200                      205

AAG GGC GTC GTG CCG GAC GAC GCC GAC AAG ATG CTC GAG TTC TTG CCC 731
Lys Gly Val Val Pro Asp Asp Ala Asp Lys Met Leu Glu Phe Leu Pro
      210                      215                      220

ACC GTG CTC GCT TGG ATC GCC GGC AAA GCG AAG TGAAGTGTGT CTGTGAGGCC 784
Thr Val Leu Ala Trp Ile Ala Gly Lys Ala Lys
      225                      230

GTGACATCGC CAGCTCGTGA CATGTGTGTT TGTGTGTGTC TGAGTCCGTC CAGTGTGTGC 844

TGAATAAATG CACCGCATGT CGTGTGTTGT ACCAAGGGCA AACAAATGCTG AATAATTTTG 904

CTGTTAAAAA AAAAAAAAAA AA 926

```

(2) INFORMATION FOR SEQ ID NO: 16: -

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 233 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

```

Met Ala Gly Asp Gly Glu Leu Lys Leu Leu Gly Val Trp Thr Ser Pro
 1           5           10           15

Phe Val Ile Arg Val Arg Val Val Leu Asn Leu Lys Ser Leu Pro Tyr
      20           25           30

```

Glu Tyr Val Glu Glu Ser Leu Gly Ser Lys Ser Ala Leu Leu Leu Gly
 35 40 45
 Ser Asn Pro Val His Gln Ser Val Pro Val Leu Leu His Gly Gly Arg
 50 55 60
 Pro Val Asn Glu Ser Gln Val Ile Val Gln Tyr Ile Asp Glu Val Trp
 65 70 75 80
 Ala Gly Ala Gly Pro Ser Val Leu Pro Ala Asp Pro Tyr Glu Arg Ala
 85 90 95
 Thr Ala Arg Phe Trp Ala Ala Tyr Val Asp Asp Lys Val Gly Ser Ala
 100 105 110
 Trp Thr Gly Met Leu Phe Ser Cys Lys Thr Glu Glu Glu Arg Ala Glu
 115 120 125
 Ala Val Ser Arg Ala Val Ala Ala Leu Glu Thr Leu Glu Gly Ala Phe
 130 135 140
 Ala Glu Cys Ser Lys Gly Lys Ala Phe Phe Gly Gly Asp Ala Ile Gly
 145 150 155 160
 Phe Val Asp Val Val Leu Gly Gly Tyr Leu Gly Trp Phe Gly Ala Ile
 165 170 175
 Asp Lys Ile Ile Gly Arg Arg Leu Ile Asp Pro Ala Arg Thr Pro Leu
 180 185 190
 Leu Ala Arg Trp Glu Glu Arg Phe Arg Ala Ala Asp Ala Ala Lys Gly
 195 200 205
 Val Val Pro Asp Asp Ala Asp Lys Met Leu Glu Phe Leu Pro Thr Val
 210 215 220
 Leu Ala Trp Ile Ala Gly Lys Ala Lys
 225 230

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1043 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA (genomic)

(1x) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:39..767

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

AGGACACGAG TATCAGGGAG GAAGACGAGG AACGTTG ATG GCC GGC GGT GAA	53
Met Ala Gly Gly Glu	
235	
GAG CTG AAG CTG CTG GGG TGG TGG GCG CCC GGG GTG AGT CCC TAC GTG	101
Glu Leu Lys Leu Leu Gly Trp Trp Ala Pro Gly Val Ser Pro Tyr Val	
240 245 250	
CTG CGC GCC CAG ATG GCG CTC GCC GTA AAG GGG CTG AGC TAC GAC TAC	149
Leu Arg Ala Gln Met Ala Leu Ala Val Lys Gly Leu Ser Tyr Asp Tyr	
255 260 265 270	
CTC CCC GAG GAC CGC TGG TCC ACG AGC GAC CTC CTC ATC GCG TCC AAC	197
Leu Pro Glu Asp Arg Trp Ser Thr Ser Asp Leu Leu Ile Ala Ser Asn	
275 280 285	
CCC GTG TAC AAG AAG GTG CCC GTC CTC ATT CAC AAC GGC AGG CCC GTC	245
Pro Val Tyr Lys Lys Val Pro Val Leu Ile His Asn Gly Arg Pro Val	
290 295 300	
TGC GAG TCG CTG CTC ATC CTG GAG TAC CTC GAC GAC GCC GTC GGC CTT	293
Cys Glu Ser Leu Leu Ile Leu Glu Tyr Leu Asp Asp Ala Val Gly Leu	
305 310 315	
GCC GGC AAC GGC AAG CCC ATC CTC CCC GCA GAC CCC TAC AGC CGC GCC	341
Ala Gly Asn Gly Lys Pro Ile Leu Pro Ala Asp Pro Tyr Ser Arg Ala	
320 325 330	
GTC GCT CGC TTC TGG GCC GCC TAT GTG AAC GAC AAG CTG TTC CCT TCG	389
Val Ala Arg Phe Trp Ala Ala Tyr Val Asn Asp Lys Leu Phe Pro Ser	
335 340 345 350	
TGC ACC GGG ATC CTC AAG ACT ACG AAG CAG GAG GAG AGA GCC GGT AAG	437
Cys Thr Gly Ile Leu Lys Thr Thr Lys Gln Glu Glu Arg Ala Gly Lys	
355 360 365	
ATG GAG GAG ACC CTG TCC GGG CTC AGA CAC TTA GAA GCT GTC ATG GCG	485

Met Glu Glu Thr Leu Ser Gly Leu Arg His Leu Glu Ala Val Met Ala
370 375 380

GAG TGC TCC GAA GGG GAG GCG GAG GCG CCG TTC TTC GGT GGT GAC GCC 533
Glu Cys Ser Glu Gly Glu Ala Glu Ala Pro Phe Phe Gly Gly Asp Ala
385 390 395

ATC GGG TTC CTC GAC ATC GCG CTC GGG TGC TAT CTT CCC TGG TTT GAG 581
Ile Gly Phe Leu Asp Ile Ala Leu Gly Cys Tyr Leu Pro Trp Phe Glu
400 405 410

GCA GCA GGC CGC CTG GCC GGC TTG GGG CCG ATC ATC GAC CCG GCG AGG 629
Ala Ala Gly Arg Leu Ala Gly Leu Gly Pro Ile Ile Asp Pro Ala Arg
415 420 425 430

ACG CCG AAA CTA GCT GCG TGG GCG GAG CGG TTC AGC GTC GCC GAG CCG 677
Thr Pro Lys Leu Ala Ala Trp Ala Glu Arg Phe Ser Val Ala Glu Pro
435 440 445

ATC AAG GCG CTG CTG CCT GGG GTC GAC AAG CTG GAG GAG TAC ATC ACT 725
Ile Lys Ala Leu Leu Pro Gly Val Asp Lys Leu Glu Glu Tyr Ile Thr
450 455 460

ACG GCG CTT TAT CCA AAG TGG AAC ATC GCG GTC ACC GGC AAC 767
Thr Ala Leu Tyr Pro Lys Trp Asn Ile Ala Val Thr Gly Asn
465 470 475

TAATTAAGA TCTTGTGTTT CCACTATGGC AAAAGAAATA AAAAGGGCG TCGTTCGATA 827
ACCGCGGAG GATCTCTGCC TTGTGAGTAG CTGTTTTCAC GTCAAGAGTT GAACTGTTAC 887
TACTAAGTCG GGTTTCTTTT TCGAGGGTT AGTGGGTCGT GGTATGAAT AATGCACAGG 947
CGTGCACTCT CTTCGATCTG AGTTGTGATA TGTGTTTCG TGAATAAATT GAAGCGTCGT1007
CGATCTTGCA TCTAAAAAAA AAAAAA 1043

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 243 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Met Ala Gly Gly Glu Glu Leu Lys Leu Leu Gly Trp Trp Ala Pro Gly
 1 5 10 15
 Val Ser Pro Tyr Val Leu Arg Ala Gln Met Ala Leu Ala Val Lys Gly
 20 25 30
 Leu Ser Tyr Asp Tyr Leu Pro Glu Asp Arg Trp Ser Thr Ser Asp Leu
 35 40 45
 Leu Ile Ala Ser Asn Pro Val Tyr Lys Lys Val Pro Val Leu Ile His
 50 55 60
 Asn Gly Arg Pro Val Cys Glu Ser Leu Leu Ile Leu Glu Tyr Leu Asp
 65 70 75 80
 Asp Ala Val Gly Leu Ala Gly Asn Gly Lys Pro Ile Leu Pro Ala Asp
 85 90 95
 Pro Tyr Ser Arg Ala Val Ala Arg Phe Trp Ala Ala Tyr Val Asn Asp
 100 105 110
 Lys Leu Phe Pro Ser Cys Thr Gly Ile Leu Lys Thr Thr Lys Gln Glu
 115 120 125
 Glu Arg Ala Gly Lys Met Glu Glu Thr Leu Ser Gly Leu Arg His Leu
 130 135 140
 Glu Ala Val Met Ala Glu Cys Ser Glu Gly Glu Ala Glu Ala Pro Phe
 145 150 155 160
 Phe Gly Gly Asp Ala Ile Gly Phe Leu Asp Ile Ala Leu Gly Cys Tyr
 165 170 175
 Leu Pro Trp Phe Glu Ala Ala Gly Arg Leu Ala Gly Leu Gly Pro Ile
 180 185 190
 Ile Asp Pro Ala Arg Thr Pro Lys Leu Ala Ala Trp Ala Glu Arg Phe
 195 200 205
 Ser Val Ala Glu Pro Ile Lys Ala Leu Leu Pro Gly Val Asp Lys Leu
 210 215 220
 Glu Glu Tyr Ile Thr Thr Ala Leu Tyr Pro Lys Trp Asn Ile Ala Val
 225 230 235 240
 Thr Gly Asn

(2) INFORMATION FOR SEQ ID NO: 19:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer"

(x1) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AGGTAGTTAC ATATGGCCGG AGGA

24

6
5
4
3
2
1
1
2
3
4
5
6